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For many years, the clinician-patient relationship has focused on two extremes: 
clinicians’ paternalism and patients’ autonomy.1 The first extreme can be seen 
as a parental or priestly model, in which the doctor knows best and uses his/her 
knowledge and skills to determine which strategy is most likely to restore the 
patient’s health.1;2 The second extreme represents more of a consumer model, 
in which the patient gathers all relevant information and selects the strategy he 
or she prefers.1;2 In their seminal 1956 paper, Szaz and Hollender added a third 
model where they defined a partnership between the clinician and the 
(chronically ill) patient.3  
In 1972, Veatch first used the term ‘sharing of decision making’ in the 
scientific literature.2 Yet, it was not until the mid-1990’s, Charles and 
colleagues’ landmark paper,4 that shared decision making gained momentum.5;6 
Prominent medical journals published articles “heralding a ‘paradigm shift’ in 
which the concept of shared decision making was said to be replacing the old 
notion that ‘doctor knows best’”.7 Nowadays, shared decision making is 
increasingly advocated as the preferred approach to making healthcare 
decisions when more than one reasonable strategy is available.4;6;8 Several 
arguments support this change to shared decision making, both from an ethical 
and a clinical point of view. Shared decision making respects and facilitates 
patient autonomy,1 and reduces unwarranted practice variation.9 By avoiding the 
provision of unwanted interventions, it may reduce health care costs and 
waste.10 Moreover, shared decision making is associated with improved patient 
satisfaction with the treatment decision and care, as well as lower anxiety and 
decisional conflict.11;12 Appropriate and timely information is a minimal and 
necessary condition for shared decision making, and these elements can help 
better manage treatment harms, and thereby reduce physical side-effects.13;14 
However, some have questioned whether this strategy is the ‘ideal’ clinician-
patient partnership because it fails to acknowledge the inherent imbalance in 
knowledge and power.1;15 Others claim that time constraints, patients’ 
incapability or the particular clinical situation may make shared decision making 
inapplicable.16;17 Indeed, in daily clinical practice, following the principles of 
shared decision making seems challenging.18;19 
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Effective versus preference-sensitive decisions 
For medical decision making, two distinct types of decisions exist: effective and 
preference-sensitive.20;21 Effective decisions have an optimal strategy available, 
as there is sufficient evidence on the effectiveness of the strategy, and possible 
benefits outweigh harms. In contrast, preference-sensitive decisions have no 
such “best strategy”. There may be insufficient evidence on the effectiveness, or 
weighing of benefits and harms strongly depends on individual (patient) values. 
While ensuring that the patient’s voice is heard is important in all healthcare 
decisions, this aspect is particularly critical for preference-sensitive decisions. 
Preference-sensitive decisions may occur within oncology, particularly relating to 
the use of (neo-)adjuvant cancer treatment. Examples include preoperative 
radiotherapy in rectal cancer, adjuvant systemic therapy in early-stage breast 
cancer, or vaginal brachytherapy in endometrial cancer. Foregoing these 
treatments is often a clinically viable option,22-24 making the involvement of 
patients in selecting the best treatment strategy crucial. Each of these clinical 
scenarios are reviewed below 
In rectal cancer, primary treatment consists of a total mesorectal resection. 
The effect of short-course (5x5 Gray) preoperative radiotherapy (PRT) on local 
control in patients with localised disease has been clearly demonstrated.25;26 
Nevertheless, due to good local control achieved with surgery alone, the number 
needed to treat to prevent one local recurrence is high.25;26 Furthermore, PRT 
has not been shown to yield a survival benefit.25;27 PRT has also been 
associated with adverse outcomes, such as higher probabilities of faecal 
incontinence and sexual dysfunction than surgery alone.26;28 It is unclear which 
patients are likely to benefit most from PRT. Research has shown large variation 
in individual patients’ treatment preferences and their valuation of the possible 
benefits and harms of treatment.29 Therefore, the Dutch medical community has 
recently acknowledged the need to involve patients in the decision making 
process in their revised guidelines on colorectal cancer treatment.22 
Current (inter-)national clinical guidelines apply relatively broad eligibility 
criteria for adjuvant chemotherapy and/or endocrine therapy in early-stage 
breast cancer.23 Due to these broad criteria, up to 60% of early-stage breast 
cancer patients may experience harms of treatment and loss of quality of life, 
without a survival benefit.30 In general, most breast cancer patients require only 
13 
 
a small beneficial effect of adjuvant treatment to consider it worthwhile, but 
again, large variation exists in individual preferences.31 This makes it essential 
to involve patients in choosing a treatment that best fits their values and 
preferences. 
Primary treatment of high-intermediate risk endometrial cancer consists of 
total hysterectomy and salpingo-oophorectomy. Postoperative vaginal 
brachytherapy (VBT) provides a significant reduction in the risk of vaginal cancer 
recurrence, but does not confer a survival benefit and is associated with adverse 
effects such as mucosal atrophy.32;33 Watchful waiting is an alternative to 
postoperative VBT, where patients are only treated with radiotherapy if they 
develop a vaginal relapse.34 However, the possible side-effects of this salvage 
radiotherapy are more severe. The five-year local control, including treatment for 
relapse, is estimated to be similar for both treatment strategies.24 Based on 
other research on cancer patients’ preferences, it may be expected that 
individual patients with endometrial cancer might value these treatment 
strategies and outcomes differently, though no studies have yet been done in 
this particular context.  
We investigated the above cases in this thesis, as they all concern 
preference-sensitive decisions and allowed us to investigate a broad spectrum 
of (neo-) adjuvant cancer treatment decisions in terms of patient population, 
treating oncologist, and tumour type. These three cases are highly suitable for 
involving patients in the decision making process, and therefore, for applying the 
principles of shared decision making.35;36 
 
Shared decision making: Definition and steps to be taken 
No widely supported or clear definition of shared decision making exists, but 
most acknowledge that clinicians and patients should work together in making 
decisions, using the best available evidence.4-6;37;38 Key words in proposed 
definitions and in the concept of shared decision making are ‘patient values’, 
‘patient preferences’, ‘options’, ‘partnership’, ‘patient participation’ and 
‘deliberation’.5 There are various theoretical models for the implementation of 
shared decision making in daily clinical practice.6;39;40 Although these models 
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differ to some extent, they all distinguish three key steps relevant to the 
adjuvant treatment decision:  
 
Step 1:  Creating choice awareness. 
The clinician defines and/or explains the problem and acknowledges 
that a decision needs to be made. Both parties should be aware that 
more than one reasonable option is available and that there is no ‘best 
choice’. If doing nothing (e.g., foregoing adjuvant treatment) is a 
clinically viable or relevant option, it should be presented as such. 
 
Step 2: Discussing treatment options in detail. 
The clinician and patient discuss the possible options in more detail. All 
relevant benefits and harms of the presented options should be 
addressed, as well as their respective probabilities. Communicating 
probabilities is complex, but in most instances essential, as 
probabilities may help weigh benefits and harms.  
 
Step 3: Discussing patients’ values and preferences and deciding what is best. 
Patients’ ideas, concerns, and expectations should be discussed and 
considered. At this stage, the patient’s preferred role in the decision 
making process might also be explored.6;41 Both parties should then 
decide what is best and agree on the course of action. This could also 
include postponing the final decision, if the patient does not feel ready 
to decide or would like to talk to a third party (such as a significant other 






Aim and outline of this thesis 
 
Taking the above key steps in shared decision making as the starting point, our 
overall aim is to assess to what extent these key steps of shared decision 
making are currently followed in preference-sensitive decisions on (neo-) 
adjuvant cancer treatment in routine clinical practice.  
 
Part I. Step 1: Creating choice awareness. 
In the first part of this thesis, we study the first and pivotal step in shared 
decision making – creating choice awareness. In Chapter 2, we assessed 
whether oncologists explicitly state that a treatment decision needs to be made 
in pre-treatment consultations for (neo-)adjuvant cancer treatment. We analysed 
pre-treatment consultations between radiation oncologists and rectal cancer 
patients regarding PRT, and between medical oncologists and breast cancer 
patients regarding chemotherapy and/or endocrine therapy. 
 
Part II. Step 2: Discussing treatment options in detail. 
The second part of this thesis focuses on the detailed discussion of treatment 
options in the context of preoperative radiotherapy in rectal cancer. Chapter 3 
describes what information radiation oncologists provide about possible benefits 
and harms of preoperative radiotherapy during the pre-treatment consultations 
with rectal cancer patients. We used these results for a follow-up study 
described in Chapter 4, where we aimed to reach consensus among radiation 
oncologists and treated patients on which benefits and harms should be 
addressed during this pre-treatment consultation. We composed a core list of 
topics that, according to our expert panels, should always be discussed. We then 
assessed congruence of our core list with routine clinical practice. Chapter 5 
focuses on communication of (neo-)adjuvant treatment risks. We examined if 
and how oncologists provide probabilistic information during the consultation, 
and how patients estimated probabilities of major treatment outcomes after this 
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consultation. In Chapter 6, we offered verbal labels (non-numerical statements) 
to convey probabilities during consultations to a representative sample of Dutch 
adults (proxies for newly-diagnosed cancer patients) to assess how individuals 
interpret these labels.  
 
Part III. Step 3: Discussing patients’ values and preferences and deciding what 
is best. 
The third part of this thesis concentrates on the final step of shared decision 
making. Chapter 7 describes the extent to which rectal cancer patients’ values 
concerning health-related benefits and harms of preoperative radiotherapy and 
patients’ treatment preferences are voiced and explicitly considered when 
deciding about treatment. In Chapter 8 we assessed the preferences of patients 
with endometrial cancer and treating clinicians regarding postoperative vaginal 
brachytherapy and a postoperative watchful waiting policy, and evaluated their 
preferred and perceived involvement in treatment decision making. 
 
Finally, in Chapter 9 the main research findings are summarized and discussed 
in the light of the broader empirical literature. We further discuss the 
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Background: The first step in shared decision making (SDM) is creating choice 
awareness. This is particularly relevant in consultations concerning preference-
sensitive treatment decisions, e.g., those addressing (neo-)adjuvant therapy. 
Awareness can be achieved by explicitly stating, as the ‘reason for encounter’, 
that a treatment decision needs to be made. It is unknown whether oncologists 
express such reason for encounter. This study aims to establish 1) if ‘making a 
treatment decision’ is stated as a reason for the encounter and if not, what 
other reason for encounter is provided, and 2) whether mentioning that a 
treatment decision needs to be made is associated with enhanced patient 
involvement in decision making. 
Material and Methods: Consecutive first consultations with 1) radiation 
oncologists and rectal cancer patients, or 2) medical oncologists and breast 
cancer patients, facing a preference-sensitive treatment decision, were 
audiotaped. The tapes were transcribed and coded using an instrument 
developed for the study. Oncologists’ involvement of patients in decision making 
was coded using the OPTION-scale. 
Results: Oncologists (N=33) gave a reason for encounter in 70/100 
consultations, usually (N=52/70, 74%) at the start of the consultation. The 
reason for encounter stated was ‘making a treatment decision’ in 3/100 
consultations, and ‘explaining treatment details’ in 44/100 consultations. The 
option of foregoing adjuvant treatment was not explicitly presented in any 
consultation. Oncologist’ involvement of patients in decision making was below 
baseline (Md OPTION-score=10). Given the small number of consultations in 
which the need to make a treatment decision was stated, we could not 
investigate the impact thereof on patient involvement.  
Conclusion: This study suggests that oncologists rarely express that a treatment 
decision needs to be made in consultations concerning preference-sensitive 
treatment decisions. Therefore, patients might not realize that foregoing (neo-) 





Shared decision making with patients (SDM) is particularly relevant when 
treatment decisions are preference-sensitive, i.e., in the absence of a clinically 
‘best choice’, or when individual patients’ valuations of the benefits and harms 
may strongly vary.1 Decisions about short-course preoperative radiotherapy 
(PRT) in rectal cancer and about adjuvant chemotherapy and/or endocrine 
therapy in early-stage breast cancer are often indeed preference-sensitive.2;3 In 
rectal cancer, PRT decreases the 5-year local recurrence risk from 11% to 6%, 
but increases the probability of adverse outcomes such as faecal incontinence 
and sexual dysfunction.4;5 There is a high number needed to treat to prevent one 
local recurrence, without a clearly demonstrated additional overall survival 
benefit.4 For early-stage breast cancer, adjuvant systemic treatment is 
recommended for patients who have a 10-year recurrence risk of 25% or more, 
and when treatment would at least yield an absolute recurrence benefit of 10%.3 
It has been argued that up to 60% of breast cancer patients only experience 
harms of adjuvant systemic treatment and loss of quality of life, with little or no 
survival benefit.6 In both the rectal and breast cancer context, the effect of    
(neo-)adjuvant treatment has been demonstrated,4;7 but difficulties arise in 
selecting those patients who will benefit from treatment. Foregoing these (neo-) 
adjuvant treatments is a clinically viable option,2;3 and given that individual 
patients may weigh benefits and harms of treatment differently,8;9 involving 
patients in treatment decision making is essential. 
In most SDM models, three key steps are distinguished: 1) explaining to the 
patient that a decision has to be made; 2) discussing all relevant treatment 
options and their associated benefits and harms; and 3) eliciting patients’ ideas, 
concerns and expectations and supporting patients in the process of 
deliberation, before reaching a decision.1;10;11 Although the first step is pivotal 
for SDM,1 it received relatively little attention in the literature so far.12 Patients 
facing a decision with marked trade-offs between benefits and harms often 
report that they were not aware that a treatment decision had to be made.13 Yet, 
most patients, including those with cancer, indicate they want an active role in 
deciding about treatment.14;15 Oncologists can create ‘choice awareness’ by 
explicitly stating that making a treatment decision is a ‘reason for the 
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encounter’. To date, there is little evidence on which reason for encounter 
oncologists express during consultations with cancer patients facing a 
preference-sensitive treatment decision. 
 
The aims of this study were to establish 1) if ‘making a treatment decision’ is 
stated as a reason for the encounter in decision-related consultations on (neo-) 
adjuvant cancer treatment, and if not, what other reason for encounter is 
provided, and 2) whether explicitly stating that a treatment decision needs to be 
made is associated with enhanced patient involvement in decision making. 
 
Materials and methods 
 
Design 
A secondary analysis was conducted of data collected in two large ongoing 
multicentre descriptive studies on (risk) communication during first 
consultations concerning (neo-) adjuvant therapy.16;17 We chose the two 
contexts of (neo-)adjuvant rectal and breast cancer treatment as they both 
concern preference-sensitive decisions and allowed us to investigate a broader 
spectrum of adjuvant treatment consultations between oncologists and cancer 
patients.  
 Consecutive first consultations - usually the only consultation prior to the 
start of the adjuvant treatment - between 1) radiation oncologists and rectal 
cancer patients, and 2) medical oncologists and breast cancer patients, were 
audiotaped. The Medical Ethics Committee of the Leiden University Medical 
Center approved both studies. Eligible patients signed an informed consent form 
prior to the consultation and completed a questionnaire to assess socio-
demographic details, either before (rectal cancer study) or after (breast cancer 




Participants were recruited in six radiation and four medical oncology outpatient 
clinics of general teaching and non-teaching hospitals, and university medical 
centers in the Netherlands. Eligible patients were 1) primary rectal cancer 
patients eligible for short-course (5x5 Gy) preoperative radiotherapy (clinical 
stage I-III), or 2) early-stage breast cancer patients eligible for adjuvant 
chemotherapy and/or endocrine therapy (pathological stage I-III). They were to 
have a good comprehension of the Dutch language. 
All radiation oncologists treating rectal cancer patients and medical 
oncologists treating breast cancer patients from the participating departments 
were invited to participate. 
 
Procedure 
We aimed to select a sample of 50 consultations each from both study 
databases using the random sampling function of IBM SPSS Statistics (version 
20). In the rectal cancer study, we balanced for gender and included all 
participating female patients in the present analyses (N=26). An equal number 
of male rectal cancer patients was then selected at random. Fifty female 
patients were randomly selected from the breast cancer study. Two patients 
were excluded from the analyses because of incomplete audiotaping. The 100 




Audiotapes of consultations were transcribed verbatim. The coding instrument 
was self-developed. One coder drafted a first version of the items and categories 
to code the reason for encounter based on four consultations. These codes were 
developed inductively, i.e., based on the data. The draft of the coding instrument 
was then complemented and refined based on 22 subsequent consultations. 
These were coded again using the final version of the coding scheme. Each 
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version of the coding scheme was discussed among the authors (MK, EE, FH, 
AP).  
 We coded whether ‘making a treatment decision’ was stated as a reason for 
encounter (yes/no), and if not, what other reason for encounter was provided 
(i.e., referral by other clinician, mentioning treatment, explaining treatment 
details, explaining treatment process; see Table 1, column 1). We further coded 
when the reason for encounter was stated and how the patient responded to the 
oncologist’s stated reason for encounter (see Table 1, column 1). Utterances of 
patients’ accompanying significant others were coded as the patients’, unless 
the patient contradicted such statements. Finally, we coded whether foregoing 
adjuvant treatment was explicitly presented as a treatment option (yes/no), and 
whether a treatment decision was made during the consultation (yes, no, 
explicitly postponed). 
Two raters independently coded the same ten audiotapes (10%) using the 
final version of the coding scheme. Inter-rater reliability was high (mean Cohen’s 
K = 0.84. Range; 0.71-1). One of the raters coded the remaining tapes. Intra-
rater reliability, based on ten tapes (10%) coded twice with a time difference of 
two months, was also high (mean Cohen’s K = 0.94. Range; 0.65-1). 
Next, the OPTION (Observing PaTient InvOlvemeNt) scale was used to 
quantify the extent to which oncologists involve patients in the decision making 
process.18 The OPTION scale measures 12 patient-involving behaviours of 
clinicians on a 0-4 scale. Inter-rater reliability of two independent raters, based 
on 10 audiotapes (10%), was substantial (Cohen’s K = 0.66). The remaining 
tapes were coded by one of the raters (Intra-rater agreement: Cohen’s K = 0.72 
and 0.93). The overall mean OPTION-scores were converted to a 0-100 scale, 
with 0 indicating no behaviour of the oncologist to involve the patient in deciding 
about treatment, to 100 indicating maximum behaviour.12 A score of 50 is 






Descriptive statistics were used to establish patients’ and oncologists’ 
characteristics, and the statements concerning the stated reasons for the 
encounter. As OPTION-scores were not normally distributed, medians are 
presented and compared by reason for encounter mentioned with Mann-Whitney 





Twenty radiation oncologists and thirteen medical oncologists audiotaped a 
median of three consultations (range, 1-7). Patients were on average 61.8 years 
old (range, 37-87). 
 
Reasons for encounter provided 
A reason for encounter was provided in 70/100 consultations (70%). The 
oncologists explicitly stated, as a reason for encounter, that a treatment 
decision needed to be made in 3/100 consultations (3%, Table 1). In these 
cases the oncologist invited patients to participate in deciding about adjuvant 
treatment by using the phrases “whether you want this adjuvant treatment”, 
“you can decide whether or not you want to do it” or “if you agree with the 
proposed treatment”. Across contexts, most often (N=44/100, 44%), the 
oncologists indicated the reason for encounter to be ‘explaining the treatment 
details’. In 17/100 consultations (17%), oncologists stated that the patient was 
there ‘for the treatment’ (e.g., radiotherapy or chemotherapy, and/or endocrine 
therapy), without specifying what they would discuss. In 30/100 consultations, 
the oncologists provided no reason for encounter. 
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All consultations N=100 N=51 N=49 
What was the oncologist’s stated reason for encounter?    
   Making a treatment decision 
   Example: “Well, the idea is that we just… give you the  
   treatment as we normally do, but in light of this  
   consultation, you can decide whether or not you…  
   want to do it.” 
  3/100   2/51 (4)   1/49 (2) 
   Explaining treatment details 
   Example: “Well, the purpose of this consultation is for  
   me to talk to you about radiotherapy, why, what you  
   can expect, and what the side effects are.” or “You are  
   here to talk about adjuvant treatment. You might  
   benefit from chemotherapy and endocrine therapy” 
44/100 20/51 (39) 24/49 (49) 
   Mentioning treatment 
   Example: “So mrs. P, you have come today for the first  
   consultation about the radiotherapy… of the rectum.” 
17/100 14/51 (27)   3/49 (6) 
   Referral by other clinician 
   Example: “Okay, you have come… you were referred…  
   for radiotherapy” 
  5/100   3/51 (6)   2/49 (4) 
   Explaining treatment process 
   Example: “What we are going to do. We… we are going  
   to explain the whole course of treatment with  
   radiotherapy and the surgery. And… then we are going  
   to sort it all out for you.” 
  1/100   1/51 (2)   0 
   No reason for encounter stated 30/100  11/51 (22) 19/49 (39) 
    
All reasons for encounter N=70 N=40 N=30 
When was the reason for encounter stated?    
   At the start of the consultation 52/70 (74) 33/40 (83) 19/30 (63) 
   At the start, but after a summary of the    
   disease/treatment process so far 
10/70 (14)   3/40 (7)   7/30 (23) 
   After history taking   6/70 (9)   2/40 (5)   4/30 (13) 
   After (part of) information provision on treatment   2/70 (3)   2/40 (5)   0 
    
How did the patient respond?    
   No reaction or minimal response 
   Example: “Yeah”, “Okay” or “Hmm” 
55/70 (79) 32/40 (80) 23/30 (77) 
   Agreement 
   Example: “Yes, that’s right” 
12/70 (17)   6/40 (15)   6/30 (20) 
   Surprise 
   Example: ”Oh, is that why I’m here?” 
  3/70 (4)   2/40 (5)   1/30 (3) 
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If the oncologist stated a reason for encounter, this was usually (N=52/70, 74%) 
done at the start of the consultation (Table 1). Patients mostly (N=55/70, 79%) 
reacted minimally or not at all to the oncologist’s reason for encounter (Table 1). 
Patients sometimes (N=12/70, 17%) responded by stating that their 
understanding of the reason for encounter was similar to that of the oncologist, 
and in a few instances (N=3/70, 4%) by stating that the oncologist’s reason for 
encounter surprised them. 
 
Treatment decision making 
In none of the consultations, including those in which the oncologist stated that 
a treatment decision needed to be made, the option of foregoing (neo-)adjuvant 
treatment was explicitly presented as a possible strategy.  
 A treatment decision was made in 56/100 consultations. The decision was 
explicitly postponed in 9/100 consultations, of which two concerned rectal, and 
seven breast cancer patients. In all other cases (N=35/100), the treatment 
decision seemed to have been made before the start of the consultation (“You 
are here because of your bowel cancer, basically, we will give you a short series 
of radiotherapy followed by surgery.”). 
 
Patient involvement in treatment decision making 
Patient involvement in decision making amounted to a median score of 10 
(range, 2-60) on a 0-100 scale. Given that only in three consultations decision 
making was mentioned as a reason for encounter, we could not investigate the 
association with patient involvement, but in these three consultations, the 








Involving patients in treatment decision making is related with improved 
satisfaction of patients with care and with the decision, and less anxiety and 
decisional conflict in patients.19 SDM is especially important when treatment 
decisions are preference-sensitive.1 Yet, even then patients often are not aware 
that a treatment decision needs to be made.13 Oncologists can create choice 
awareness in patients and facilitate SDM by explicitly stating, as a reason for 
encounter, that a treatment decision needs to be made. To the best of our 
knowledge, the current study is the first to assess whether choice awareness is 
created in preference-sensitive decision consultations. 
In this study, we examined the reasons for encounter given during first 
consultations of oncologists and cancer patients facing a preference-sensitive 
decision concerning (neo-)adjuvant cancer treatment. In only 3% of the 
consultations the need to make a treatment decision was found to be made 
explicit. Rather, the oncologists indicated that the reason for encounter was for 
them to explain the treatment details. Interestingly, in none of the 100 
consultations, including those in which the need to make a treatment decision 
was expressed, the option of foregoing (neo-)adjuvant treatment was explicitly 
addressed. This is not in line with informed consent norms. Moreover, choosing 
between two possible treatment strategies might feel less burdensome to 
patients than declining the one treatment the oncologist has on offer.20 Only if 
patients are offered a balanced view of possible treatment strategies, they will 
be prevented from consenting to treatments that go against their informed 
values and preferences.21-23  
 
In this study, we also aimed to assess whether explicitly mentioning that a 
treatment decision needs to be made is associated with enhanced patient 
involvement in decision making. Unfortunately, we were unable to do so 
because oncologists expressed this need to make a treatment decision in 
almost none of the consultations. 
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 Patient involvement in the decision making process was quite low. This is 
reflected by the OPTION-scores as compared to other studies in oncology using 
this scale and to the norm for baseline skills.12 A possible explanation for the low 
level of patient involvement is that in roughly one-third of the consultations a 
treatment decision seemed to have been made before the start of the 
consultation. This most probably had been done during the multidisciplinary 
team (MDT) meeting. Oncologists might then consider the treatment 
recommendation from the MDT as the one best treatment, thus leaving less 
room for patients’ values and preferences to be incorporated in the final 
decision. In previous research, we also showed that oncologists’ behaviour to 
involve patients in treatment decision making was limited, but that at the same 
time, oncologists do believe they apply the principles of SDM in daily practice.24 
Our findings reflect the limited skills of the oncologists in SDM and points to the 
need for thorough training to support the implementation of SDM in clinical 
practice. 
 
A strength of our study is that we were able to observe actual communication in 
a broad spectrum of consultations between oncologists and cancer patients and 
that we did not depend on oncologists’ or patients’ recall or interpretation on 
whether ‘making a treatment decision’ was addressed. A possible limitation of 
our study is that although the Dutch national rectal and breast cancer treatment 
guidelines provide room to opt for different treatment strategies,2;3 we do not 
have information on the extent to which oncologists perceived a treatment 
choice. Future research should therefore focus on assessing oncologists’ 
perceptions of the viability of declining adjuvant treatment, and especially on 
oncologists’ reasoning behind these perceptions. Given that patients’ valuations 
of treatment and of benefits and harms of treatment vary,8;9 and given that the 
treatment guidelines already consider these treatment decisions to be 
preference-sensitive,2;3 choice awareness might have to be created in 
oncologists as well. 
 
In conclusion, creating awareness of treatment choice is considered to be 
pivotal for SDM, but it has received little attention in the literature so far. Our 
results show that during preference-sensitive decision consultations on adjuvant 
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cancer treatment, oncologists rarely express that a treatment decision needs to 
be made. Thus, they miss a crucial opportunity to create choice awareness in 
patients and engage patients in an SDM process. Instead, oncologists seem to 
use the consultation to explain the one treatment strategy they recommend. We 
expect that creating awareness in patients of treatment choice, thus taking the 
first step of SDM, will provide more opportunities for oncologists and patients to 
collaborate in selecting the best possible course of action and thus improve 
patient outcomes. Indeed, adequately creating choice awareness among 
patients might be a simple, cheap, yet effective step in empowering patients to 
participate in treatment decision making and helping them to receive the 
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Background: For shared decision making to be successful, patients should 
receive sufficient information on possible benefits and harms of treatment 
options. The aim of this study was to evaluate what information radiation 
oncologists provide during the decision consultation about preoperative 
radiotherapy with rectal cancer patients. 
Methods: Decision consultations of 17 radiation oncologists with 81 consecutive 
primary rectal cancer patients, eligible for short-course radiotherapy followed by 
a low anterior resection, were audiotaped. Tapes were transcribed and analyzed 
using the ACEPP (Assessing Communication about Evidence and Patient 
Preferences) coding scheme. 
Results: A median of seven benefits/harms were addressed per consultation 
(range, 2-13). This number ranged within and between oncologists and was not 
clearly associated with the patient’s characteristics. A total of 30 different 
treatment outcomes was addressed. The effect of radiotherapy on local control 
was addressed in all consultations, the effect on survival in 16%. The most 
important adverse effects are bowel and sexual dysfunction. These were 
addressed in respectively 82% and 85% of consultations; the latter significantly 
less often in female than in male patients. Four out of five patients did not 
initiate discussion on any benefits/harms. 
Conclusion: Our results showed considerable inconsistency between and within 
oncologists in information provision, which could not be explained by patient 
characteristics. This variation indicates a lack of clarity on which benefits/harms 
of radiotherapy should be discussed with newly-diagnosed patients. This 
suboptimal patient information hampers the process of shared decision making, 
in which the decision is based on each individual patients’ weighing of benefits 






In 2012, about 380 000 new cases of rectal cancer were diagnosed worldwide, 
and this number is increasing annually.1 Primary treatment consists of total 
mesorectal excision (TME). The effect of short-course (5x5 Gy) preoperative 
radiotherapy (PRT) on local control in patients with localized disease has been 
clearly demonstrated.2 However, difficulties arise in selecting those patients who 
benefit most from PRT, with a high number needed to treat to prevent one local 
recurrence.2;3 Furthermore, PRT is associated with adverse effects, the most 
important of which are bowel problems and sexual dysfunction.3;4 
Large differences exist between individual rectal cancer patients’ treatment 
preferences and their valuation of  possible benefits and harms of treatment.5 
These preferences cannot be predicted based on socio-demographic factors or 
disease characteristics.6 This situation, in which individual patients weigh 
possible benefits and harms of treatment differently, is highly suitable for shared 
decision making.7;8 
In general, rectal cancer treatment guidelines make little or no 
recommendations on which benefits and harms to communicate to patients. The 
Dutch guidelines on colorectal cancer state that clinicians should “discuss the 
possible benefits and harms of radiotherapy with the patient”, without specifying 
which benefits and harms.9 Informing patients about possible treatment options 
and associated outcomes is a minimal and necessary condition for eliciting and 
considering patient preferences and for involving them in treatment decision 
making. Moreover, it helps to meet cancer patients’ information needs.10 
Patients who are well-informed and have a clear understanding of their 
preferences regarding treatment outcomes, experience less anxiety.11 In 
addition, appropriate and timely information can help provide better 
management of cancer treatment side effects, and thereby reduce physical side 
effects.12;13 The majority of treated cancer patients, however, indicate that they 




This study aimed to evaluate the information provision during the first 
consultation between radiation oncologists and rectal cancer patients, in which 
the decision about PRT is usually made. Research questions to be answered 
were: (1) Which benefits and harms of PRT are addressed in the consultation? 
(2) Are benefits and harms addressed on the initiative of the radiation 
oncologist, the patient or a companion? and (3) If variation in the benefits and 
harms addressed or in the initiation of these is seen, is this variation associated 
with patient characteristics? 
 
Materials and methods 
 
Study population 
This study was conducted in four of the 18 radiotherapy centers in the 
Netherlands. All primary rectal cancer patients eligible for short-course (5x5 Gy) 
preoperative radiotherapy followed by a low anterior resection, with a good 
comprehension of the Dutch language, were eligible for inclusion. All radiation 
oncologists treating rectal cancer patients were asked to participate. 
 
Procedure 
Inclusion of patients started in one radiation center and was gradually extended 
to the other centers. Decision consultations of participating radiation oncologists 
with all consecutive eligible primary rectal cancer patients scheduled to undergo 
a low anterior resection were audio taped. The Medical Ethics Committee of 
Leiden University Medical Center approved the study. Eligible patients signed an 
informed consent form and completed a self-report questionnaire to assess 
socio-demographic details before the consultation started. Radiation oncologists 
were asked to fill in a questionnaire assessing their socio-demographic and 




Audio tapes of consultations were transcribed verbatim and analyzed using the 
ACEPP (Assessing Communication about Evidence and Patient Preferences) 
coding scheme.15 By using this scheme, all health related benefits and harms of 
PRT that were discussed in the consultation were identified. Benefits and harms 
related to inconvenience or costs, such as travel time or expenses, were not 
included. Two raters independently coded the same 10 (12% of total number) 
audiotapes. Inter-rater reliability was high (Cohen’s K = 0.83).16 The remaining 
tapes were coded individually (intra-rater agreement based on eight (10%) tapes 
per rater coded twice with a time difference of 19 months, Cohen’s K= 0.78-
0.85). 
 
Statistical analyses  
Descriptive statistics were used to report patients’ and radiation oncologists’ 
characteristics, and information provision on benefits and harms of PRT. The 
number of benefits and harms addressed per consultation was not normally 
distributed, so medians are presented and compared with Mann-Whitney U 
tests. Spearman correlations were used to measure linear dependence between 
number of benefits/harms addressed and consultation time. A logistic 
regression analysis was conducted to predict the discussion of benefits/harms, 
using age as a predictor. Using χ2 tests, initiative of patients and clinicians to 
discuss benefits and harms was compared. Significance testing was done two-











In total, 112 eligible patients, diagnosed between November 2010 and March 
2013, were asked to participate. Of them, 84 agreed (response rate 75%). Three 
patients were excluded from the analyses because their consultation had not 
(completely) been recorded. All 17 radiation oncologists treating patients with 
rectal cancer agreed to participate and audio taped a median of five 
consultations with new rectal cancer patients (range, 1-11). In Table 1 patient 
and clinician characteristics are listed. 
 
Table 1. Participant characteristics. 
 N (%) 
Patients (N=81)  
Mean age, years ± s.d. (range) 65 ± 10.4 (40-87) 
Male  57 (70) 
Partner (yes) a 51 (76) 
Educational level a, b  
   Low 20 (30) 
   Intermediate 30 (45) 
   High 16 (24) 
Companion in consultation 73 (90) 
  
Clinicians (N=17)  
Mean age, years ± s.d. (range) 39 ± 6.3 (27-50) 
Male   5 (29)* 
Median time since specialization, years (range) 4 (0-20) 
Median number of rectal cancer patients per month (range) 3 (1-8) 
a Fourteen patients did not complete the self-report questionnaire. 
b Educational levels included low = completed no/primary school; intermediate = completed lower 
general secondary education/vocational training; or high = completed pre-university education/high 
vocational training/university. One patient did not respond to this question. 
* Male radiation oncologists audio taped a total of 20 (25%) consultations. 
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Benefits and harms addressed per consultation  
Figure 1 shows the variation in the number of benefits and harms addressed per 
consultation both between and within radiation oncologists. Overall, a median of 
seven benefits and harms were addressed per consultation (range, 2-13). There 
was no significant association between the number of benefits and harms 
addressed and patient gender, age, or educational level.  
Overall, consultations lasted significantly longer when more benefits and 
harms were addressed (median=33 minutes for ≤6 benefits/harms vs 40 
minutes for 7≥ benefits/harms, rho = .23, p<0.05). 
 
 
Figure 1. Number (median and range) of benefits and harms addressed in consultations per 
radiation oncologist, sorted by median.  
Abbreviation: N = number of consultations taped per radiation oncologist. 
 
In the 81 audio taped consultations, a total of 30 different benefits and harms 
of PRT in rectal cancer were addressed (see Figure 2). The beneficial effect of 
PRT on local control of the cancer was addressed in all consultations. The effect 
of PRT on overall survival was addressed in 13 (16%) consultations, conducted 
by five (29%) different radiation oncologists.  
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Figure 2. Benefits and harms of PRT addressed in decision consultations.  
Abbreviations: ST = on the short term; LT = on the long term. *As a percentage of consultations with 
patients from relevant patient group (male/female patients). 
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The most important adverse effects of PRT described in the literature are bowel 
problems and sexual dysfunction. Bowel problems, such as altered defecation 
pattern, fecal incontinence or rectal blood loss, were addressed in 66 (82%) 
consultations, conducted by 15 (88%) different radiation oncologists. In 53 
(65%) consultations short-term bowel problems during treatment were 
discussed, and in 57 (70%) consultations long-term bowel problems were 
discussed, with a high within-patient overlap. There was no significant 
association between discussing bowel problems and patient gender, age, or 
educational level. 
Long-term sexual dysfunction, such as erectile or ejaculation disorders (male 
patients), vaginal dryness (female patients), or sexual problems in general 
(without further specification) was addressed in 69 (85%) consultations, 
conducted by 16 (94%) different radiation oncologists, and significantly less 
often in female than in male patients (N=16, 67% vs N=53, 93% respectively; 
χ2= 7.56, p<0.01). Although not statistically significant, the older the patients 
were, the less often sexual dysfunction was discussed during the consultation 
(p=0.07). There was no association between discussing sexual dysfunction and 
patient’s educational level or marital status. 
 
Initiative to address benefits and harms 
Across consultations, radiation oncologists initiated 89% of the discussions 
about benefits and harms. The other discussions were initiated by the patients 
(9% of benefits/harms) or the patients’ companions (2% of benefits/harms), for 
example by asking a question or addressing a new topic. In total, there were 16 
patients (20%) who showed initiative during their consultation to discuss at most 
two harms (e.g., skin irritation, feeling unwell, bladder dysfunction, long term 
fecal incontinence, fatigue, nerve damage, secondary tumors, muscle weakness 
and abdominal wound healing problems). Topics that companions additionally 
raised were anastomotic leakage, overall survival and sexual dysfunction.  
In consultations in which the patient initiated the discussion of a harm, a 
median of two more benefits/harms were addressed compared to consultations 
with more passive patients (Md=8 vs 6, p<0.05). There was no significant 
association between whether or not a patient took the initiative to raise a topic 
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This study aimed to examine what information is provided about possible 
benefits and harms of PRT in the first consultation between newly-diagnosed 
rectal cancer patients and their radiation oncologist, in which a decision about 
PRT is usually made.  
Our study showed considerable variation, both in the number and in the type 
of benefits and harms that were discussed. This variation was present between 
as well as within radiation oncologists and could not consistently be explained by 
patients’ characteristics. The variation found implies that some patients receive 
limited information, while other patients are informed extensively. It is a 
necessary condition for informed consent and shared decision making alike, 
that all patients receive sufficient information on possible benefits and harms of 
treatment options.17 At the same time, the more information is given, the less 
patients usually remember.18 Depending on the total amount of information 
given, it is expected that about 40-80% of this information is forgotten 
immediately after the consultation,19 though this percentage should decrease 
when clinicians tailor their information to patients’ frame of reference.20;21 
Another potential drawback of extending information-giving to patients, is that 
placebo research in other settings have shown that patients tend to report 
experiencing side effects they have been warned about.21 These caveats do not 
imply that information should not be provided, but rather highlight the 
importance of consensus about which benefits and harms should be presented 
to newly-diagnosed rectal cancer patients. 
The beneficial effect of PRT on local control was addressed in all 
consultations. In contrast, the effect on overall survival was discussed in a small 
portion of consultations only. This finding might not come as a surprise given 
that PRT does not improve overall survival in this patient group.2 However, if the 
absence of a survival benefit is not made explicit in the consultation, many 
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patients might wrongly assume that increased local control will result in 
increased overall survival. Discussing both topics prevents patients from 
interpreting information wrongly, and will help them develop realistic 
expectations on the possible benefit of treatment.  
PRT is associated with several adverse effects, such as bowel and sexual 
dysfunction.4 Both topics were addressed in the majority of consultations, but 
over one in four patients did not receive information on the effect of PRT on long 
term bowel dysfunction, whilst half of irradiated rectal cancer patients will 
experience some form of fecal incontinence. Sexual dysfunction was addressed 
in a large majority, however more often with male than with female patients. 
Because of the high prevalence of in particular long term bowel and sexual 
dysfunction in patients treated with PRT, and the lack of gain in overall survival, 
our findings show that there is still much room for improvement in information 
provision. Furthermore, if these topics are not discussed during the consultation, 
the trade-off between possible benefits and harms as the basis for the 
treatment recommendation might not be clear to the patient. 
It is noteworthy that radiation oncologists occasionally addressed benefits or 
harms which have not been described in the literature (e.g., increased or 
decreased rectal blood loss) or which do not hold for short-course (5x5 Gy) 
preoperative radiotherapy (e.g., tumor downsizing). This highlights the need for a 
core list of topics to be addressed or not during the consultation with newly-
diagnosed rectal cancer patients. In a follow-up study, we intend to seek 
consensus between rectal cancer patients and radiation oncologists on which 
benefits and harms of PRT should be addressed with all newly-diagnosed rectal 
cancer patients during the decision consultation. This follow-up study will result 
in a core list of topics that need to be addressed. As the national treatment 
guidelines are a reference for clinicians, the core list will be included in the 
revised national guidelines on colorectal cancer. Further implementation 
strategies, such as the use of communication checklists or leaflets in addition to 
the oral communication, need to be considered in the future. 
Radiation oncologists initiated the discussion of most of the benefits and 
harms addressed. About four out of five patients did not initiate discussion on 
any benefits/harms. It has been shown that cancer patients are often unsure 
about what they should ask their clinician,22;23 but the lack of patients’ initiative 
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could also imply that they perceive their radiation oncologists to be 
comprehensive. When patients actually take the initiative to discuss outcomes 
of treatment, significantly more benefits and harms were discussed in the 
consultation. This implies that outcomes that the patient brings forward add to 
the outcomes that the clinician already addresses. 
A limitation of this study is that we present quantitative data. Conclusions 
cannot be drawn about the quality of information provision on benefits and 
harms of PRT, nor about the consistency of quality between and within radiation 
oncologists. Furthermore, because of relatively small numbers of patients 
included per radiation oncologist, we were unable to assess associations 
between the variation in benefits and harms discussed and oncologists’ 
characteristics. Finally, it is noteworthy that we only have data on information 
provision during patient’s consultations with the radiation oncologist, and not 
during earlier consultations with other clinicians, such as the surgeon or the 
gastroenterologist. Future research should focus on establishing whether 
information provision is consistent and sufficient across specialties. 
In conclusion, our results showed considerable variation in information 
provision during the decision consultation on PRT regarding possible benefits 
and harms of PRT in rectal cancer. This variation indicates a lack of clarity on 
which benefits and harms of PRT should be discussed with a newly-diagnosed 
patient. Radiation oncologists should be aware of this between and within-
clinician variation. Standardizing information provision and making sure that all 
relevant benefits and harms are discussed with each individual patient would 
not only help to meet patients’ information needs, it would also promote a 
process of shared decision making about radiotherapy, in which treatment 
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Background and Purpose: We previously found considerable variation in 
information provision on preoperative radiotherapy (PRT) in rectal cancer. Our 
aims were to reach consensus among patients and oncologists on which 
benefits/harms of PRT should be addressed during the consultation, and to 
assess congruence with daily clinical practice.  
Materials and Methods: A four-round Delphi-study was conducted with two 
expert panels: 1) 31 treated rectal cancer patients and 2) 35 radiation 
oncologists. Thirty-seven possible benefits/harms were shown. Participants 
indicated whether addressing the benefit/harm was 1) essential, 2) desired, 3) 
not necessary, or 4) to be avoided. Consensus was assumed when ≥80% of the 
panel agreed. Results were compared to 81 audio-taped consultations. 
Results: The panels reached consensus that six topics should be addressed in 
all patients (local control, survival, long term altered defecation pattern and 
faecal incontinence, perineal wound healing problems, advice to avoid 
pregnancy), three in male patients (erectile dysfunction, ejaculation disorder, 
infertility), and four in female patients (vaginal dryness, pain during intercourse, 
menopause, infertility). On average, less than half of these topics were 
addressed in daily clinical practice.  
Conclusions: This study showed substantial overlap between benefits/harms 
that patients and oncologists consider important to address during the 





Preoperative radiotherapy (PRT) improves local control of rectal cancer. Although 
not demonstrated in randomised controlled trials, there might be a small 
survival benefit at the population level.1;2 Due to the good local control with 
surgery alone, there is a high number needed to treat to prevent one local 
recurrence.2;3 In addition, PRT is associated with adverse outcomes, such as 
higher chances of bowel and sexual dysfunction than with surgery alone.3;4 
When deciding about treatment, the possible benefit in terms of local control 
should therefore be balanced against the possible harms, taking into account 
patient preferences. Patients need to be informed about the most relevant 
benefits and harms of treatment in order to develop a preference. Informing 
patients also prevents them from overestimating the impact of treatment on 
cure.5 Moreover, patients who are well-informed experience better health-related 
quality of life and may cope better with treatment side effects.6;7 
In earlier research, we found considerable variation in information provision 
regarding benefits and harms of PRT during the decision consultation between 
rectal cancer patients and their radiation oncologist.8 This variation indicates a 
lack of clarity on which benefits and harms of PRT should be discussed with 
newly-diagnosed patients. In general, treatment guidelines provide little or no 
recommendation on which benefits and harms to communicate to patients. The 
Dutch guidelines for the treatment of rectal cancer for example state that 
clinicians need to ‘discuss the possible benefits and harms of radiotherapy with 
the patient’, without further specification.9  
 
The aims of this study were to 1) reach consensus among rectal cancer patients 
and radiation oncologists and compose a core list of benefits and harms of PRT 
that should minimally be addressed during the decision consultation, and 2) 




Materials and methods 
 
Participants 
A Delphi study was performed in two panels: treated rectal cancer patients and 
radiation oncologists. One of the most critical requirements in the Delphi method 
is the selection of experts, rich in information and experience.10 Eligible patients 
had received radiotherapy and had finished their oncologic treatment at least 
four months ago. Patients treated at the Leiden University Medical Center who 
participated in an earlier study were approached via mail. Furthermore, 
members of the Dutch colorectal cancer patient organization were approached 
through the monthly newsletter of their association. Members of the 
Gastrointestinal-subsection of the Dutch Society for Radiation Oncology were 
approached for participation. All 45 radiation oncologists who were member of 
this platform were considered to be clinical experts. 
We aimed to include at least half of the radiation oncologists from the 
platform, and an equal number of rectal cancer patients.  
 
Design 
In order to reach consensus, we used the Delphi technique. This is a structured 
process that uses a series of questionnaires or ‘rounds’ to gather information 
until consensus in the panels is reached.11 As we expected differences in 
opinions between patients and radiation oncologists, we aimed to reach 
consensus in each panel separately.12 Based on previous Delphi studies, we 
intended a maximum of three online rounds in which participants could indicate 
which benefits and harms should always be addressed during the decision 
consultation.11 Since there was only consensus on a limited number of 
benefits/harms after three rounds, we organized additional and separate 
consensus meetings with a fourth and final voting round. Between January and 
September 2013, the participants completed an iterative series of four 
questionnaires with feedback reports. In the first online questionnaire, socio-
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demographic and treatment- (patients) or work- (radiation oncologists) related 
details were obtained. 
To assess congruence between the results of this Delphi-study and daily 
clinical practice, we compared the core list that was obtained to results of a 
previous study on information provision regarding benefits and harms of PRT.8 In 
that study, we audiotaped and analyzed 81 decision consultations between 
radiation oncologists and rectal cancer patients. 
 
Questionnaire rounds 
The first questionnaire consisted of 37 benefits and harms, ordered by subject 
matter (see Table 1). These were obtained from all benefits/harms that had 
been discussed in any of the first 45 of 81 previously audio taped decision 
consultations between radiation oncologists and rectal cancer patients.8 
Benefits/harms related to inconvenience or costs were excluded. We 
complemented the list with outcomes described in the literature.2;3;13-18 This led 
to a total of 30 outcomes on which PRT could have an effect for all patients, 
three for male patients only, and four for female patients only. In both panels, 
the same brief description of the items was given to help minimize interpretation 
differences. Information on probable prevalence was given in words and ranges 
(rare: 0-5%; sometimes: 5-25%; often: 25-75%; (almost) always: 75-100%). 
Participants were asked to indicate whether they thought that addressing the 
outcome during the first consultation was 1) essential, 2) desired, 3) not 
necessary, or 4) to be avoided. Participants were asked to respond to all 
outcomes. For example, all participants (including female patients) were asked 
to indicate the importance of addressing ‘erectile dysfunction’ during 
consultations with male patients. After each subject matter, participants could 
comment on the item descriptions or suggest additional outcomes. The first 
questionnaire was pilot-tested in eight radiation oncologists and eight lay 




Table 1. Benefits and harms of preoperative radiotherapy presented in the first Delphi-round. 
1. Local control 
2. Overall survival 
3. Secondary tumours 
4. Altered defecation pattern (short term) 
5. Altered defecation pattern (long term) 
6. Faecal incontinence (short term) 
7. Faecal incontinence (long term) 
8. Soiling 
9. Increased rectal blood loss 
10. Decreased rectal blood loss 
11. Small bowel adhesions 
12. Bladder dysfunction 
13. Urinary incontinence 
14. Infertility (women) 
15. Infertility (men) 
16. Avoidance of pregnancy 
17. Erectile dysfunction (men) 
18. Ejaculation disorder (men) 
19. Vaginal dryness (women) 
20. Pain during intercourse (women) 
21. Menopause (women) 
22. Anastomotic leakage 
23. Increased blood loss during surgery 
24. Abdominal wound healing problems 
25. Perineal wound healing problems 
26. Increased readmission rate 
27. Nerve damage (short term) 
28. Nerve damage (long term) 
29. Muscle weakness 
30. Skin irritation 
31. (Local) Hair loss  
32. Fatigue 
33. Longer recovery 
34. Feeling unwell 
35. Less appetite 






Based on literature, we defined consensus as at least 80% of the participants in 
one panel ticking the same answer category (e.g., 1 ‘essential’) and no more 
than 15% an answer category two or three categories away (e.g., 3 ‘not 
necessary’ or 4 ‘avoid’).11 Outcomes on which consensus was reached were 
removed from the subsequent questionnaire(s). The other items were included 
in the subsequent questionnaire, together with feedback on the responses of 
the panel and the participant’s own responses. Radiation oncologists also 
received feedback on patients’ responses. Feedback on participants’ responses 
in each of the categories was shown as a percentage and a column bar. In the 
second and third questionnaire, participants were asked to reconsider their 
previously given responses in light of the opinion of other panel members.  
 
Consensus meetings 
After the three online questionnaires, we organized a separate in-person 
consensus meeting for each panel, with the aim to discuss the importance of 
addressing benefits/harms for which no consensus had been reached in the 
online rounds. All participants who had completed the third round were invited. 
The meetings started with a brief presentation on the background of the study, 
followed by the results up to then. After a group discussion on the importance of 
addressing the benefits and harms, participants’ final opinions were assessed 
anonymously.  
At the consensus meeting, several participants indicated that the response 
categories 1 (essential) and 2 (desired) were only marginally different. We 
therefore decided to merge these categories in the analysis of the responses in 
this final round. 
 
Statistical analyses 
Responses of patients and radiation oncologists were analyzed separately. 
Descriptive statistics were used to report patients’ and radiation oncologists’ 
characteristics, their views on which benefits and harms should be addressed 
and congruence between the results of this study and daily clinical practice. 
62 
Using Chi-square tests and Mann-Whitney U tests, characteristics and responses 
of participants who did versus did not complete the study were compared. A two-




Of the 38 eligible patients approached, 23 (61%) completed the first 
questionnaire. An additional eight were included through the patient 
organization. Of these 31 patients, 28 patients completed the second and third 
questionnaire (90% of those who started). Ten patients attended the consensus 
meeting and completed the final voting round (36% of those who completed the 
third questionnaire). 
Of the 45 radiation oncologists who are member of the platform, 35 (78%) 
completed the first questionnaire. The second and third questionnaire were 
completed by 32 and 29 oncologists, respectively (91 and 83% of started, 71 
and 64% of total). All 29 oncologists who completed the third round also 
completed the final voting round. 
In Table 2 participant demographic and treatment- (patients) or work- 
(oncologists) related characteristics are listed. Radiation oncologists working at 
a non-teaching center compared to an academic or non-academic teaching 
center significantly more often declined further participation in the study (N=4, 
44% vs N=1, 8% vs N=1, 7%; χ2=6.36, p<0.05). Otherwise, no significant 
differences were found between characteristics of participants who did versus 
did not complete the study. To assess bias caused by the 36% response rate of 
the consensus meeting, we compared the scores in round 3 of attenders and 
non-attenders. We found that patients who attended the consensus meeting 
rated ‘bladder dysfunction’ as significantly more important than patients who did 
not attend the consensus meeting (χ2=10.04, p<0.01). After receiving feedback 
on the answers given in round 3 and a discussion during the consensus 
meeting, patients eventually reached consensus that this outcome need not 
necessarily be discussed. Otherwise, no significant differences were found 
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between the answers of those who did versus those who did not attend the 
consensus meeting. 
 
Table 2. Participant characteristics in round 1. 
 N (%) 
Patients (N=31)  
Member of patient association 10 (32) 
Mean age, years ± s.d. (range) 64 ± 10.7 (32-85) 
Mean time since diagnosis, years ± s.d. (range) 2 ±  2.2 (0.3-9) 
Male 18 (58) 
Educational level a  
   Low   2 (7) 
   Intermediate 16 (55) 
   High 11 (38) 
Neo-adjuvant treatment  
   PRT (5x5 Gy) 19 (61) 
   Chemoradiation 12 (39) 
Stoma  
   No stoma 12 (34) 
   Temporary 11 (36) 
   Permanent   8 (26) 
  
Radiation oncologists (N=35)  
Mean age, years ± s.d. (range) 47 ± 8.1 (35-66) 
Mean time since specialization, years ± s.d. (range) 12 ± 9.0 (  2-39) 
Mean number of new rectal cancer patients per month ± s.d. (range)   5 ± 2.3 (  1-10) 
Male 12 (34) 
Current institution  
   Academic teaching center 14 (40) 
   Non-academic teaching center 12 (34) 
   Non-teaching center   9 (26) 
a Educational levels included low = completed no/primary school, intermediate = completed lower 
general secondary education/vocational training; or high = completed pre-university education/high 





Patients and radiation oncologists reached consensus on, respectively, 29 and 
30 of the 37 benefits/harms. Both panels agreed that six benefits/harms should 
be addressed with all newly-diagnosed rectal cancer patients, together with 
three benefits/harms for male patients only and four for female patients only. 
They also agreed that 11 benefits/harms need not always be addressed. 
According to the panels, none of the benefits/harms should be avoided during 
the first consultation. The final core list of benefits/harms that should be 
addressed and items that need not necessarily be addressed can be found in 
Table 3a and 3b. 
 
Table 3a. Benefits and harms of PRT that should be addressed with newly-diagnosed rectal cancer 
patients, and number of rounds needed by expert panel before reaching consensus 
Consensus on benefits/harms that  
should be addressed: 
Patients reached 
consensus in round:  
Oncologists reached 
consensus in round:  
1. Local control 4 4 
2. Survival 4 3 
3. Altered defecation pattern (long term) 3 4 
4. Faecal incontinence (long term) 4 4 
5. Perineal wound healing problems 4 4 
6. Advice to avoid pregnancy a 1 3 
7. Erectile dysfunction 1 3 
8. Ejaculation disorder 1 4 
9. Infertility 1 4 
10. Vaginal dryness 4 4 
11. Pain during intercourse 3 4 
12. Menopause b  2 1 
13. Infertility b  2 1 
Consensus in patients only:   
- Increased readmission rate 4 - 
Consensus in clinicians only:   
- Altered defecation pattern (short term) - 4 
- Nerve damage (short term) - 4 
a Men and premenopausal women only 
b Premenopausal women only 
Light grey shades refer to benefits/side effects concerning male patients only, dark grey shades 
refer to benefits/side effects concerning female patients only. 
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Table 3b. Benefits and harms of PRT that need not be addressed with newly-diagnosed rectal cancer 
patients, and number of rounds needed by expert panel before reaching consensus 
Consensus on benefits/harms that  
need not necessarily be addressed: 
Patients reached 
consensus in round:  
Oncologists reached 
consensus in round:  
1. Faecal incontinence (short term) 4 3 
2. Increased rectal blood loss 4 3 
3. Decreased rectal blood loss 4 3 
4. Increased blood loss during surgery 4 3 
5. Nerve damage (long term) 4 2 
6. Skin problems 4 4 
7. (Local) Hair loss  4 3 
8. Feeling unwell 4 3 
9. Less appetite 4 1 
10. Cardiovascular problems 4 4 
11. Fistula 4 4 
Consensus in patients only:   
- Bladder dysfunction 4 - 
- Abdominal wound healing problems 4 - 
- Muscle weakness 4 - 
- Fatigue 4 - 
Consensus in clinicians only:   
- Secondary tumours - 2 
- Small bowel adhesions - 3 
- Urinary incontinence - 4 
- Anastomotic leakage - 2 
 
In total, there were 11 topics on which one panel reached consensus, and the 
other panel did not. On two topics, patients’ and oncologists’ opinions were 
almost contrary. Patients agreed that ‘increased readmission rate’ should be 
addressed, while oncologists approached consensus that this is not necessary 
(72% agreement). Also, oncologists agreed that ‘short-term altered defecation 
pattern’ should be addressed, while patients tended to rate this as ‘not 





To assess congruence between the results from the Delphi-study and daily 
clinical practice, we compared the core list to results on information provision 
regarding benefits and harms of PRT, based on 81 audiotaped decision 
consultations.8 We found that in daily clinical practice, male patients received 
information on 3.3 (37%) of the nine topics from the core list (range, 1-6) on 
average. Female patients on average received information on 3.2 (32-46%) of 
the seven topics from the core list for postmenopausal women or 10 topics for 
premenopausal women (range, 1-6). In none of the 81 audiotaped 
consultations, all benefits/harms as defined in the core list were addressed. As 
can be seen in Figure 1, only the effect of PRT on local control was addressed in 
all consultations. There were seven (9%) consultations in which local control was 
the only topic from the core list that was addressed.  
 
 
Figure 1. Topics which should be addressed and the percentage of consultations in which the 
benefit/harm was addressed.  
Abbreviations: ST = on the short term; LT = on the long term. * as a percentage of consultations with 
patients from relevant patient group (male/female patients). ‡ Only relevant for patients undergoing 
abdominoperineal resection, all patients in our sample underwent a low anterior resection. Black 
bars = consensus in both panels, Grey bars = consensus in radiation oncologist panel only. 
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Several topics which are not on the core list are frequently addressed in 
consultations. Both panels reached consensus that ‘skin problems’ and ‘feeling 
unwell’ are not necessary to address in the first consultation. In daily clinical 
practice, these topics were addressed in 27 and 31% of the consultations, 
respectively. In addition, the patient panel agreed that ‘fatigue’ and ‘bladder 
dysfunction’ need not necessarily be addressed. In respectively 53 and 70% of 




The first aim of this study was to reach consensus among rectal cancer patients 
and radiation oncologists on which benefits and harms of PRT should minimally 
be addressed in the decision consultation. The patient and oncologist panels 
agreed that six benefits/harms should be addressed with all newly-diagnosed 
rectal cancer patients, together with three benefits/harms for male patients only 
and four for female patients only. It is noteworthy that all topics in the final core 
list are long-term benefits/harms. Indeed, during the consensus meeting, 
patients indicated to be less interested in temporary short-term effects. The 
long-term benefits/harms include the effect of PRT on local control, survival, 
defecation and sexual functioning, and these effects are well-established and 
described in the literature.1-3  
Of particular interest are the topics on which panels had different opinions. 
Firstly, oncologists reached consensus that ‘short-term altered defecation 
pattern’ should be addressed during the consultation, but patients’ opinion 
differed. This might be due to the fact that most patients already experience an 
altered defecation pattern at the time of the consultation. Secondly, oncologists 
agreed that ‘short-term nerve damage’ should be addressed, while patients’ 
opinions were divided. Because of the very low prevalence of short term nerve 
damage and patients’ bias towards their own experiences, it might be difficult 
for patients to understand the consequences of this harm, despite the 
description we provided. This lack of consensus highlights that oncologists 
should be aware that patients’ information needs might differ from what they 
themselves consider important to address. 
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The second aim of the study was to assess congruence between the core list 
and daily clinical practice. We found that patients received information on a 
limited number of topics from the core list. On average, less than half of the 
topics from the list were addressed during the consultation. Even more 
importantly, almost one in ten patients received no information on any of the 
adverse effects that should have been addressed, according to both patients 
and radiation oncologists. The need for implementing this list in daily clinical 
practice is therefore clearly demonstrated.  
Panels agreed that several topics not necessarily need to be addressed with 
newly-diagnosed patients. Some of these topics are nevertheless discussed in a 
large part of the audiotaped consultations. Possible reasons to address these 
topics may have to do with patient characteristics or patient’s question asking 
behaviour. In previous research we found that four out of five patients did not 
initiate discussion on any benefits/harms by asking questions or raising new 
topics. Furthermore, no clear association between benefits/harms mentioned 
and patient’s characteristics such as gender, age or educational level was seen. 
However, factors like co-morbidity and medical history of individual patients 
might give a reason to discuss certain additional topics. 
 
Our study has some limitations. Firstly, although we pilot-tested our 
questionnaire and panellists were given the opportunity to comment on the 
questionnaire in each round, participants only indicated during the consensus 
meeting that the meaning of the answer categories ‘essential’ and ‘desired’ was 
only marginally different. We decided to merge these categories in the analysis 
of the responses on the final round. Had we started the Delphi study with three 
categories, consensus on some topics might have been reached earlier. 
Secondly, of the 28 patients who completed the third questionnaire, only 10 
patients attended the consensus meeting and completed the final 
questionnaire. However, the characteristics of patients who attended compared 
to those who declined further participation did not differ significantly. Although 
there was a significant difference in how attending and non-attending patients 
valued the discussion of ‘Bladder irritation’, the attenders converged to the 
opinion of the larger group of non-attenders on this topic. . Finally, we have no 
information on which adverse effects of PRT the members of our patient panel 
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experienced during or after their treatment. Therefore, we cannot make any 
statements on the influence of patients’ own experience on their views about 
whether or not to address the benefits/harms offered in our questionnaire. 
 
Delphi-methods have been used before in order to develop core lists. However, 
so far no studies have been published on core lists of benefits and harms of 
treatment to be communicated to patients during the consultation. Even though 
previous research has shown that cancer patients have a strong need for 
information about side effects of treatment,19;20 our study showed that treated 
patients are capable of prioritizing those benefits/harms they think are 
necessary to address during the consultation. Therefore, patients’ perspectives 
are valuable when creating core lists. The method we used thus seems feasible 
for creating core lists for other treatments and other cancer types. As can be 
seen from a number of recent publications, the interest in the sequelae of rectal 
cancer treatment, and other cancer treatments as well, is rising.21;22 Our study is 
thus timely in showing a feasible method to determine which such sequelae 
should be communicated with patients during the consultation. 
 
In conclusion, our results showed substantial overlap between which benefits 
and side effects of PRT patients and radiation oncologists consider important to 
address in the first consultation. These topics were poorly addressed in daily 
clinical practice. Our core list can be supplemented with outcomes of relevance 
to the individual patient. Addressing information on these major outcomes of 
PRT will better enable individual rectal cancer patients to balance possible side 
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Objective: Probabilities of benefits and harms of treatment may help patients 
when making a treatment decision. This study aimed to examine 1) whether and 
how radiation oncologists convey probabilities to rectal cancer patients, and 2) 
patients’ estimates of probabilities of major outcomes of rectal cancer 
treatment. 
Methods: First consultations of oncologists and patients eligible for preoperative 
radiotherapy (PRT) (N=90) were audiotaped. Tapes were transcribed verbatim 
and coded to identify probabilistic information presented. Patients (N=56) filled 
in a post-consultation questionnaire on their estimates of probabilities. 
Results: Probabilities were mentioned in 99% (local recurrence), 75% 
(incontinence), 72% and 40% (sexual dysfunction in males and females, 
respectively) of cases. Most patients (89%) correctly estimated that PRT 
decreases the probability of local recurrence, and 10% and 38%/54% that it 
increases the probability of incontinence and sexual dysfunction in 
males/females, respectively. Patients tended to underestimate the probabilities 
of harms of treatment. 
Conclusion: Our results show that oncologists almost always mention 
probabilities of benefit of PRT. In contrast, probabilities of harms often go 
unmentioned. The effect of PRT on adverse events is often underestimated. 
Practice implications: Oncologists should stay alert to patients’ possible 
misunderstanding of probabilistic information and should check patients’ 




Determining the best choice when facing a treatment decision can be difficult 
for both clinicians and patients. Over the past decades, patients have become 
more actively involved as partners in the decision making process.1 In particular 
for ‘preference-sensitive’ decisions, i.e., decisions for which there is insufficient 
evidence or in which individuals might value benefits and harms of treatment 
markedly differently, shared decision making (SDM) has become increasingly 
important.2 One such preference-sensitive decision is the decision on neo-
adjuvant short-course preoperative radiotherapy (PRT) in the treatment of 
localized rectal cancer.3 The beneficial effect of PRT on local control in patients 
with localized rectal cancer has been clearly demonstrated.4 However, PRT has 
not been shown to convey an additional survival advantage4 and is associated 
with a higher risk of adverse effects, most importantly faecal incontinence and 
sexual dysfunction.5-7 Difficulties arise in selecting those patients who benefit 
most from PRT, which makes it even more relevant to enable individual patients 
to weigh the benefits and harms of treatment for themselves. 
In the process of SDM, the clinical consultation is an opportunity for patients 
to learn about their treatment options, including no adjuvant treatment, the 
benefits and harms of each option, and to be supported in making decisions.8 
Communicating probabilities that are relevant to the treatment decision is 
complex but essential, as probabilities often are the foundation of clinicians’ 
treatment recommendation and help determine the importance of potential 
benefits and harms. Research has shown that the format (i.e., words, numbers) 
in which probabilistic information is presented can have significant effects on 
patients’ interpretation of probability and their readiness to undergo 
treatments.9-11 If probabilistic information is presented in words rather than in 
numbers, patients tend to have a less accurate interpretation of probabilities 
and overestimate the probability of an adverse event occurring.11-14 
Furthermore, presenting patients with relative risks appears more persuasive in 
making health care decisions than presenting the corresponding absolute risks.9 
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To date, research on effective methods for risk communication has primarily 
focused on written communication and the textual or visual representation of 
probabilities, including the application of these methods in decision aids.15-17 To 
our knowledge, research on oral risk communication during clinical 
consultations in which treatment decisions are made has received no attention. 
 
This study had a dual objective. The first aim of the study was to examine 
whether and how radiation oncologists provide probabilistic information, 
specifically in what proportion of risk statements they convey a probability using 
words, numbers, or both, and whether these proportions or the overall number 
of probabilities mentioned is associated with patients’ age, gender and 
educational level. The second aim was to examine patients’ estimates of 
probabilities of major outcomes of rectal cancer treatment (local control, faecal 
incontinence, sexual dysfunction), namely, if patients’ estimates are correct and 
whether correct estimates is associated with the format used to communicate 





The study was conducted at six of the 18 radiation centres in the Netherlands in 
the context of a large ongoing multicentre study on communication and 
treatment decision making during first consultations on PRT. All rectal cancer 
patients eligible for short-course PRT followed by a low anterior resection 
(sphincter-saving operation, with a possible risk of faecal incontinence), were 
eligible for inclusion. All radiation oncologists treating patients with rectal cancer 





First consultations, in which the decision about PRT is usually made, of radiation 
oncologists with consecutive primary rectal cancer patients were audio taped. 
Participating patients signed an informed consent form and completed a 
questionnaire to assess socio-demographic details prior to the consultation. 
Patients were also asked to fill in a questionnaire within one week of the 
consultation, to assess their estimates of probabilities of major outcomes of 
rectal cancer treatment. Patients who filled in the post-consultation 
questionnaire more than 14 days after the consultation were excluded from the 
analyses (N=3). Radiation oncologists were asked to fill in a questionnaire 
assessing their socio-demographic and work-related details at the start of the 
study. 




Audio tapes of consultations were transcribed verbatim and coded using the 
ACEPP (Assessing Communication about Evidence and Patient Preferences) 
coding scheme.18 By using this scheme, presented evidence relating to 
treatment outcomes was identified. Utterances conveying a probability of a 
patient experiencing benefit and/or harms of treatment were coded as a word 
(‘verbal label’), a number, or both, as applicable. If a verbal label was used, we 
coded whether the label conveyed a direction of the effect of PRT (‘yes’, e.g., 
smaller chance; or ‘no’, e.g., small chance). If a number was used, we coded 
whether a percentage, a natural frequency (e.g., “5 out of 100”), or both were 
used. Also, we coded whether the number represented an absolute risk (e.g., “5 
out of 100” or “35%”), an absolute risk reduction (e.g., “5% less chance” or 
“60% of patients with treatment, but 20% of patients fewer without treatment”), 
a relative risk (e.g., “twice as likely” or “will halve your risk”), or a range around 
risk (e.g., “about 30-40 patients”). If multiple formats were used to express 
numerical probabilities on one benefit/harm, all formats used were coded and 
therefore, categories of numbers mentioned do not add up to 100%.  
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Two independent raters coded the same ten (11%) audiotapes. Inter-rater 
reliability was high (Cohen’s K = 0.80). The remaining tapes were each coded by 
one rater only; intra-rater reliability based on eight (9%) tapes per rater coded 
twice with a time difference of 19 months was substantial (Cohen’s K = 0.67-
0.92). 
The major benefit of PRT described in the literature is local control, and 
major harms are faecal incontinence and sexual dysfunction. In the post-
consultation questionnaire, patients were asked to indicate side-by-side the 
absolute probability ranges of each of these three outcomes occurring as a 
result of one of two treatment strategies: surgery only and PRT followed by 
surgery (multiple-choice questions, see Figure 1). The question on local control 
was framed in terms of ‘local recurrence’, as we expected this framing to be 
used in communicating probabilities in daily clinical practice. The question on 
sexual dysfunction was matched to the patient’s gender. For each outcome, we 
considered patients’ answers to be correct if they could reproduce the numerical 
probabilities that their oncologist had mentioned (i.e., risk recall). If no numerical 
probability was mentioned, we considered patients’ answers to be correct if they 
ticked the probability ranges for the group averages, as reported in key 
publications and in the Dutch treatment guidelines (i.e., risk 
interpretation).3;7;19;20 From this point forward, recall and interpretation will be 
referred to as ‘estimate’. If patients’ responses indicated that with PRT followed 
by surgery, compared to surgery only, the probability of a local recurrence is 
lower, or that the probability of faecal incontinence or sexual dysfunction is 








Of 100 people who have been treated for a tumour in the rectum, in how many will the disease 
recur within 5 years after treatment with ... 
a)… radiotherapy followed by surgery? b)… surgery only? 
      no one 
      1 to 5 
      6 to 10 
      11 to 15 
      16 to 20 
      more than 20 
      no one 
      1 to 5 
      6 to 10 
      11 to 15 
      16 to 20 
      more than 20 
 
Of 100 people who have been treated for a tumour in the rectum, how many will experience 
leakage of stools in the years after treatment with ... 
a)… radiotherapy followed by surgery? b)… surgery only? 
      no one 
      less than 30 
      30 to 50 
      51 to 70 
      more than 70 
      no one 
      less than 30 
      30 to 50 
      51 to 70 
      more than 70 
 
Only for MEN: 
 
Of 100 men who have been treated for a tumour in the rectum, how many will be confronted 
with sexual problems (erection problems and/or ejaculation problems) in the years after 
treatment with ... 
a)… radiotherapy followed by surgery? b)… surgery only? 
      no one 
      less than 40 
      40 to 60 
      61 to 80 
      more than 80 
      no one 
      less than 40 
      40 to 60 
      61 to 80 
      more than 80 
 
Only for WOMEN: 
 
Of 100 women who have been treated for a tumour in the rectum, how many will be confronted 
with sexual problems (vaginal dryness and/or pain during intercourse) in the years after 
treatment with ... 
a)… radiotherapy followed by surgery? b)… surgery only? 
      no one 
      less than 10 
      10 to 20 
      21 to 30 
      31 to 40 
      more than 40 
      no one 
      less than 10 
     10 to 20 
      21 to 30 
      31 to 40 
      more than 40 
Figure 1. Multiple-choice questions on the interpretation of risks of major outcomes of PRT. 
Correct answer boxes per outcome and treatment strategy are ticked and were based on  
key publications and on the Dutch treatment guidelines. 
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Statistical analyses 
Descriptive statistics were used to report patients’ and radiation oncologists’ 
characteristics, and information provision on the probability of patients 
experiencing benefits and/or harms of treatment. The overall number of 
probabilities mentioned and the number of verbal labels, numbers, or both used 
per consultation were not normally distributed, so medians are presented and 
were compared by patients’ gender and patients’ interpretation with Mann-
Whitney U-tests. Spearman correlations were used to measure linear 
dependence between overall number of probabilities addressed and number of 
verbal labels, numbers or both used, and patients’ age. Logistic regression 
analysis was conducted to assess the association between the discussion of 
probabilities (yes/no) and patients’ age. Using χ2 tests, patients’ correct 
estimate of probabilities (yes/no) and patients’ correct estimate of the effect of 
PRT (yes/no) were compared by oncologists’ use of verbal labels only and by 






We approached 128 eligible patients, all diagnosed between November 2010 
and April 2014. Twelve patients (9%) could not be reached and twenty-one 
(17%) refused to participate. Ninety-five patients (74%) agreed to have their 
consultation audio taped. Five of them were excluded from the analyses 
because their consultation had not been audio taped completely. Of the 
remaining 90 patients, 56 (62%) completed the post-consultation questionnaire, 
a median of five days after the consultation (range, 0-13). Patients were on 
average 64 years old (range, 40-87), and the majority (73%) were male (Table 
1). No significant differences were found for patients’ age, gender or educational 
level between those who did versus did not complete the post-consultation 
questionnaire. All 21 radiation oncologists approached for the study agreed to 
participate and audiotaped a median of four consultations (range, 1-11). 
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Table 1. Participants’ characteristics 
 N 
Patients (N=90)  
   Mean age, years ± s.d. (range) 64 ± 10.1 (40-87) 
   Male  66 (73%) 
   Educational levela  
      Low 17 (33%) 
      Intermediate 32 (44%) 
      High 26 (22%) 
Radiation oncologists (N=21)  
   Mean age, years ± s.d. (range) 40 ± 6.5 (27-52) 
   Male   6 (29%)b 
   Median time since specialization, years (range) 6 (0-20) 
   Median number of rectal cancer patients per month (range) 3 (1-8) 
a Educational levels included low = completed no/primary school; intermediate = completed lower 
general secondary education/vocational training; or high = completed pre-university education/high 
vocational training/university. Eighteen patients did not respond to this question. 
b Male radiation oncologists audio taped a total of 19 consultations (21%). 
 
Oncologists’ overall provision of probabilistic information on benefits/harms 
In the 90 consultations, 611 benefits and harms of PRT were mentioned (Md=7 
per consultation; range, 2-12) (Table 2). The oncologists mentioned the 
probability of their occurrence for 358 benefits and harms (59%, Md=4 per 
consultation; range, 0-8). The oncologists mentioned significantly fewer 
probabilities in consultations with less compared to more educated patients (Md 
‘Low education’=3, ‘Intermediate education’=4, ‘High education’=5 probabilities 
per consultation, F(2,69)=7.52, p=0.001). There was no significant association 
between the number of probabilities the oncologists mentioned and patients’ 







Table 2. Communication of probabilities of treatment outcomes of PRT followed by surgery and 



























(incl major)  
N (%) 




89 (99) 51 (57) 61 (91) 15 (63) 216 611 
       
When outcome is 
addressed 
N=89 N=51 N=61 N=15 N=216 N=611 
Probability 
mentioned  
88 (99) 38 (75) 44 (72)   6 (40) 176 (81) 358 (59) 




N=88 N=38 N=44 N=6 N=176 N=358 
Verbal label only  12 (14) 19 (37) 24 (39)   3 (50)   58 (33) 220 (61) 
Number only  24 (27)   9 (18) 11 (18)   2 (33)   46 (26)   57 (16) 
Verbal label and 
number  
52 (58) 10 (20)   9 (15)   1 (17)   72 (41)   81 (23) 
       
When a verbal 
label is 
mentioned 
N=64 N=29 N=33 N=4 N=131  
Direction of PRT-
effect mentioned 
57 (89) 20 (69) 20 (61)   3 (75) 100 (77)  
       
When a number 
is mentioned* 
N=76 N=19 N=20 N=3 N=118  
Percentage 52 (68) 18 (94) 17 (81)   2 (67)   89 (75)  
Natural 
Frequency 
12 (16)   1   (5)   0   0   13 (11)  
Absolute risk 18 (24) 11 (58) 11 (55)   1 (33)   41 (35)  
Absolute risk 
reduction 
49 (64) 13 (68)   9 (45)   1 (33)   72 (61)  
Relative risk 52 (68)   2 (26)   2 (10)   0   54 (46)  
Range around 16 (21)   7 (37)   2 (10)   1 (33)   26 (22)  
Abbreviations: PRT = Preoperative radiotherapy; LR = Local recurrence; F. Inc = Faecal Incontinence; 
Sex M = Sexual dysfunction males; Sex F = Sexual dysfunction females.  * Categories of numbers 
mentioned do not add up to 100%, because multiple categories can apply to a probability statement. 
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Patients’ estimates of probabilities 
The patients selected the correct absolute probability ranges of both surgery 
only and PRT followed by surgery, in 12/56 cases (21%) for local recurrence, 
0/52 cases (0%) for faecal incontinence, 3/39 cases (8%) for sexual dysfunction 
in males, and 4/14 cases (29%) for sexual dysfunction in females.  
Patients had a slight tendency to overestimate the probability of a local 
recurrence for treatment with surgery only (Figure 2a). For PRT followed by 
surgery, patients’ estimates of a local recurrence were spread across categories. 
All patients underestimated the probability of faecal incontinence for PRT 
followed by surgery, and the majority (61%) of patients also underestimated the 
probability for surgery only (Figure 2b). For both treatment strategies, male 
patients tended to underestimate the probability of sexual dysfunction (Figure 
2c). Female patients’ estimates of the probability of sexual dysfunction were 
spread across categories, with a slight tendency to overestimate the probability 
for surgery only and to underestimate the probability for PRT followed by surgery 
(Figure 2d). 
 
Table 3 shows the percentage of patients who correctly interpreted the effect of 
PRT, compared to surgery only, on the major treatment outcomes. Most patients 
(89%) correctly interpreted that PRT decreases the probability of a local 
recurrence. Regarding faecal incontinence and sexual dysfunction in males and 
females, the patients correctly interpreted that PRT increases the probability in 
10%, 38% and 54%, respectively. Of note, over one-third (38%) of patients 
believed that PRT decreases the probability of faecal incontinence. There were 







Figure 2a. Patients’ estimates of probabilities of local recurrence 





Figure 2b. Patients’ estimates of probabilities of faecal incontinence 





Figure 2c. Patients’ estimates of probabilities of sexual dysfunction (males) 





Figure 2d. Patients’ estimates of probabilities of sexual dysfunction (females) 







Table 3. Patients’ interpretation of the effect of PRT followed by surgery on major treatment 

















PRT decreases probability 89% 38% 13% 15% 
PRT does not influence probability   9% 52% 49% 31% 
PRT increases probability   2% 10% 38% 54% 
Abbreviation: PRT = Preoperative radiotherapy. Grey boxes represent the correct effect of PRT 
followed by surgery, compared to surgery alone. a Four patients did not respond to this question.        
b Two patients did not respond to this question. 
 
There was no significant association between the oncologists’ use of either 
verbal labels only or numbers (with or without verbal labels) or the number of 
probabilities the oncologists mentioned during the consultation and whether 
patients correctly estimated the absolute probabilities or the direction of the 
PRT-effect on the treatment outcomes. Also, there was no significant association 
between whether the oncologists conveyed a direction of the effect of PRT 
(either by verbal labels or numbers) and patients’ correct estimate of the effect 
of PRT. Further, there was no significant association between patients’ age, 
gender or educational level and whether patients correctly estimated the 
absolute probabilities or the direction of the PRT-effect on the treatment 
outcomes. 
 
Discussion and conclusion 
 
Discussion 
The first aim of this study was to describe the oncologists’ provision of 
probabilistic information, and specifically in what proportion of cases when the 
oncologists mention a benefit/harm of treatment, they also convey a probability. 
Almost two-third of the times that a benefit or harm was discussed, the 
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oncologists also mentioned the probability of its occurrence, albeit significantly 
less frequently to patients with lower education. The major benefit of PRT 
described in the literature is local control, and major harms are faecal 
incontinence and sexual dysfunction. Earlier, we showed that oncologists as well 
as patients consider these topics important to address during the first 
consultation.21 The current study showed that the (decreased) probability of 
local recurrence, the benefit of PRT, is virtually always mentioned during the 
consultation. In contrast, probabilities of major harms of PRT often go 
unmentioned. An explanation of the discrepancy may lie in two factors. The first 
may be that oncologists simply do not know the probabilities of the major harms 
as well as they know the probability of local recurrence. Another explanation may 
lie in the fact that oncologists think that PRT is the best option for the patient, 
and they either implicitly or explicitly use the persuasive strategy of selectively 
presenting the benefits of treatment.22 Further, it is noteworthy that oncologists 
do not only discuss sexual dysfunction significantly more often with male than 
with female patients, as has been shown in previous research,23 but they also 
mention its probability substantially more often to male patients. Not mentioning 
the probabilities of possible harms has been shown to be associated with less 
understanding of these harms and an increased acceptance of interventions 
that might do harm.24 
 When presenting probabilities of local recurrence, oncologists tended to 
present a relative risk, stating that PRT will cut by half its probability of 
occurrence. In a majority of these cases, the oncologists also gave information 
on the baseline absolute risk or the absolute risk reduction. Adding this 
information should be helpful to patients’ understanding. Indeed, it has been 
shown that when relative risks are not accompanied by an absolute risk, they 
can steer patients towards accepting a treatment or intervention, since 
particularly with low baseline risks a relative risk reduction seems larger than an 
absolute risk reduction and the effect of treatment thus seems larger.17  
The second aim of this study was to examine patients’ estimates of 
probabilistic information on major treatment outcomes, and specifically if 
patients’ estimates were correct. This was true for few patients. We were unable 
to find significant associations between formats used to convey probabilities 
and the correctness of patient’s estimates, which might have been due to the 
limited number of patients returning the questionnaire. 
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In the majority  the cases in which a probability of a major outcome was 
mentioned, the oncologists used a number, with or without the accompaniment 
of a verbal label. In one-third of the cases, only verbal labels were used. The 
latter should be discouraged as previous research has shown that the accuracy 
of patients’ interpretation and patients’ satisfaction are lower when only verbal 
labels are used, compared to when numbers are mentioned.11;12 We found that 
patients tend to overestimate the probability of getting a local recurrence if 
adjuvant treatment with radiotherapy is foregone (e.g., treatment with surgery 
alone). Also, we found that patients tend to underestimate the probability of 
harms occurring after radiotherapy treatment. The findings of an overestimation 
of the small probability of local recurrence and an underestimation of the large 
probabilities of incontinence and sexual dysfunction are in line with prospect 
theory.25 Since our crude way of assessing over- and underestimation is unlike 
the general way of assessment in prospect theory research, however, we are not 
sure whether it truly reflects the concept of probability distortion specified by this 
theory. This deserves further research. 
We did not find an effect of the use of verbal labels only on patients’ 
estimates of probabilities, possibly due to the small sample size of patients. In a 
systematic review on risk communication, Zipkin and colleagues recommended 
to improve patients’ understanding by avoiding the use of verbal labels only, a 
recommendation which is widely supported.15-17;26 Also, literature suggests that 
the use of illustrations or icon arrays might aid patients’ understanding.26 
 Most, though not all, patients interpreted the effect of PRT on local 
recurrence correctly. In contrast, the effect of PRT on faecal incontinence and 
sexual dysfunction was most often estimated incorrectly. For example, over one-
third of patients believed that PRT followed by surgery, compared to surgery 
only, decreases the probability of faecal incontinence, while in fact, PRT 
increases the risk from about 40 to 60%.27 This suggests that many patients 
believe that there is no harm in undergoing PRT. There may be several 
explanations for patients’ misinterpretations. Firstly, patients might not consider 
these harms important given the potential gain, and especially at this point in 
time when they are primarily focused on becoming disease-free. In earlier 
research, however, we found that rectal cancer patients consider both faecal 
incontinence and sexual dysfunction important topics to be discussed with the 
radiation oncologist at the time of decision making, and that they take these 
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harms in consideration when forming a treatment preference.21;28 Secondly, 
patients might ignore these probabilities, as they believe that the treatment 
decision has already been made. In most of these first consultations, 
oncologists do not tell the patient that a treatment decision needs to be made.29 
This might lead to post hoc justification, that is, to patients having the desire to 
justify the prior decision as being the correct one, and one which will do them no 
harm.30 
 
A strength of our study is that by audio taping the consultations, we were able to 
observe the actual communication between radiation oncologists and rectal 
cancer patients and therefore, we did not depend on oncologists’ or patients’ 
recall on which probabilities were mentioned. Our study also has potential 
limitations. The first is that because of relatively small numbers of patients 
included per oncologist, we were unable to assess associations between 
probabilities mentioned and oncologists’ characteristics. Further, the range in 
the number of recorded consultations per oncologist might have led to 
somewhat skewed results. The second limitation is that only 57 of the 90 
patients included in the study filled in the post-consultation questionnaire 
(within 14 days). Most (22/33, 67%) of the patients who did not complete the 
questionnaire only gave consent for audiotaping their consultation. Other 
patients returned the questionnaire without filling in the questions on risk 
interpretation, possibly because they did not know the answers or were 
uncomfortable with the questions. If this is the case, then the rates of correct 
estimates of probability ranges that we established, most probably are 
overestimations of actual understanding. Finally, patients might have received or 
searched for additional (probabilistic) information prior to the consultation or 
after the consultation and before completing the questionnaire. Again, this 
would imply that our results overestimate the number of patients who correctly 
estimate the probabilities of treatment outcomes based on the information 






Our results show that the probability of the additional benefit of PRT on local 
control is virtually always mentioned during the first and pre-treatment 
consultation. In contrast, probabilities of adverse events are often left unspoken. 
Most patients interpret the beneficial effect of PRT on local control correctly, but 
the effect of PRT on adverse events is most often underestimated. 
 
Practice implications 
In order for patients to understand and weigh the pros and cons of treatment, 
and in order for them to be involved in deciding about treatment, they need to 
be aware of the relevant probabilities of major outcomes. This is a challenge for 
oncologists who should be careful to mention both the probabilities of benefit 
and harms whenever possible and stay alert to patients’ potential 
misunderstanding. It is recommended that oncologists regularly check patients’ 
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Do oncologists convey what they 
intend? Lay interpretation of verbal 
risk labels used in decision 
consultations






Background: Probabilities of benefits and harms of treatment may help patients 
making a treatment decision. Oncologists frequently use verbal labels only (non-
numeric statements) to convey a probability. This study aimed to assess the 
numerical probability that patients associate with verbal labels and the influence 
of medical outcome, age, gender, educational level, health literacy and 
numeracy. 
Materials and methods: Frequently-used verbal labels (N=11) were extracted 
from N=90 audiotaped decision consultations. A sample of the adult Dutch 
population (N=300), as proxies for newly-diagnosed cancer patients, assigned 
numerical probabilities to the labels and filled in a questionnaire on their socio-
demographic characteristics, health literacy and numeracy.  
Results: Considerable variation was seen in how individuals interpreted the 
verbal labels. Participants’ probability estimates of verbal labels was lower in the 
context of cancer recurrence compared to nausea. Low numerate participants 
tended to differentiate less between the labels. The same tendency was found 
for educational level and health literacy, but not statistically significant. There 
was no association between participants’ estimates and age or gender. 
Discussion: Our results showed considerable variation in how individuals 
interpret verbal labels frequently-used, with medical outcome and numeracy as 
possible determinants. It is recommended to avoid the use of verbal labels only, 






In medical consultations, oncologists frequently use verbal labels (non-numeric 
probability statements) to convey a probability of an event occurring.1 Primary 
reasons to use verbal labels is lack of availability of numerical information, and 
uncertainty about the actual numerical probability for a specific patient.2 Also, 
compared to numbers, verbal labels are easy and natural to use, and may better 
capture a person’s emotions, intuitions, and directionality.2-4 On the other hand, 
using verbal labels has the potential weakness of a high degree of variability in 
interpretation.3 That is, the magnitude of the probability that an oncologist aims 
to convey using a verbal label may not be interpreted as such by a patient. This 
variability could especially be problematic when oncologists communicate 
probabilities that are relevant to treatment decision making. Probabilities often 
are the foundation of oncologists’ treatment recommendations and they better 
enable patients to weigh the benefits and harms of different treatment 
strategies. We recently showed that in medical consultations with newly-
diagnosed rectal cancer patients facing a treatment decision, in one-third of the 
cases, radiation oncologists only use verbal labels to convey a probability, in 
spite of the potential pitfall of variability in interpretation. Of note, in this clinical 
case numerical probabilities are available and known to most oncologists.1 
The way in which probabilities are presented can have a significant effect on 
patients’ interpretation and their readiness to undergo treatment.5 More than 
with numerical probabilities, the interpretation of verbal labels can be influenced 
by the assumed frequency of an event occurring and by its severity, with people 
assigning higher numerical probabilities to verbal labels concerning high 
frequent or less severe events.6-8 The influence of other determinants such as 
age, gender, educational level, health literacy and numeracy has been 
investigated to some extent, but is still equivocal.2;9-11 To the best of our 
knowledge, no research has been conducted on the simultaneous influence of 
these determinants, nor on the interpretation of verbal labels that are frequently 





This study aimed to assess the numerical probability that individuals associate 
with verbal labels used to convey probabilities of outcomes in cancer treatment 
decision consultations, and the association with type of treatment outcome and 
individuals’ characteristics. Research questions to be answered were: 1) How do 
individuals from the general adult population (as proxies for newly-diagnosed 
cancer patients facing a treatment decision) interpret frequently-used verbal 
labels, in the context of two outcomes of cancer treatment? and 2) Is there an 
association between individuals’ interpretation of verbal labels and the type of 
outcome, individuals’ age, gender, educational level, health literacy, or 
numeracy? 
 
Materials and methods 
 
Design 
An online questionnaire was offered to a sample representative for the adult 
Dutch population, in which participants were asked to rate verbal labels, 
regarding one of two outcomes of rectal cancer treatment. Verbal labels were 




The sample consisted of 300 adult Dutch participants, stratified to mirror the 
adult census population in terms of age, gender and educational level. For 
taking part in this study, participants received credits from a research agency, 






Procedure and measures 
In preparation of the online questionnaire, we extracted utterances conveying a 
probability of a patient experiencing a treatment benefit or harm by use of a 
verbal label.1;12 To this end, we used data collected during a large multicenter 
study on (risk) communication regarding short-course preoperative 
radiotherapy.1 Consecutive consultations (N=90) between radiation oncologists 
and newly-diagnosed rectal cancer patients facing a treatment decision were 
audiotaped and coded. Verbal labels were selected for the current study from 
those most frequently used that covered a wide range in 1) wording of the labels 
and 2) probabilities conveyed with the verbal labels. Only verbal labels 
expressing an absolute risk were selected. Expressions containing a negation 
(e.g., not often) were excluded. This resulted in a list of 11 frequently-used 
verbal labels, which covered 71% of all verbal labels used during the 90 
consultations. 
The research agency invited members of their panel to participate by sending 
them a link to the questionnaire. Participants were given a short introduction 
stating that “to convey a probability that someone experiences for example a 
side-effect of treatment, clinicians may use probability words, such as often or 
sometimes”. Next, they were asked to complete socio-demographic details. They 
were then either directed to the questionnaire or redirected back to the website 
of the research agency if the maximum number of participants with their 
characteristics had been reached. Participants directed to the questionnaire 
were randomized to one of two outcomes of rectal cancer treatment: 1) ‘A 
patient will be treated with radiotherapy because of rectal cancer. A 
disadvantage of radiotherapy is that people can get nauseous’; or 2) ‘A patient 
will undergo surgery because of rectal cancer. In spite of this surgery, the cancer 
could come back.’ The situations were chosen such that they presented realistic 
outcomes of the treatment and that they differed in seriousness. To increase 
comparability and to best mimic current clinical practice, both were framed 
negatively. Characteristics of participants were comparable across the two 
groups (data not shown). Participants were offered the 11 verbal labels each as 
part of a short sentence (i.e., “sometimes people become nauseous”) and in 
random order. They were asked to indicate how many people in their view will 
experience this outcome, by filling in a natural frequency (both the numerator 
and the denominator: “approximately … out of … people”).  
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After rating the verbal labels, participants filled in a short questionnaire on 
health literacy and numeracy.13;14  
 
Statistical analyses 
Descriptive statistics were used to report the participants’ characteristics and 
numerical estimate of each verbal label. Frequencies were converted to 
percentages. An overall numeracy score was calculated by averaging the ratings 
across all numeracy items. The classification of participants’ health literacy and 
numeracy levels (inadequate/adequate and lower/higher, respectively) was 
based on recommendations of the questionnaire developers.15;16  
We tested differences in the numerical probabilities that individuals 
associated with the verbal labels (within-subject levels) by medical outcome, 
age, and gender (between-subject factors) using repeated measure general 
linear models, adjusted using the Greenhouse-Geisser method. As we expected 
that individuals with a lower educational level, inadequate health literacy, or 
lower numeracy discriminate less between high and low probabilities and thus, 
assign lower probabilities to labels conveying a higher chance and higher 
probabilities to those conveying a lower chance,10;17 we also tested whether 
there was a difference in the numerical probabilities individuals associated with 
the ‘low’ versus ‘high’ verbal labels depending on educational level, health 





In total, 4902 people were invited to participate, and 994 (20%) began the 
survey. After filling in their socio-demographic details, 499/944 people were 
redirected from the questionnaire, because the maximum of participants with 
their characteristics had already been reached. All other participants (N=495) 
were directed to the questionnaire. Thirteen of them were excluded from the 
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analyses, because they filled in the same numbers for all verbal labels. A total of 
300/482 (62%) participants completed the questionnaire, in a median time of 
4.9 minutes (Table 1). 
 
Table 1. Participants’ characteristics (N=300) 
 N (%) 
Age   
   20-39 years   99 (33) 
   40-64 years 145 (48) 
   65-80 years   56 (19) 
Male gender 151 (50) 
Educational levela  
   Low   47 (16) 
   Intermediate 168 (56) 
   High   84 (28) 
Health literacy  
   Inadequate 110 (37) 
   Adequate 190 (63) 
Subjective numeracy  
   Low, median score on 1-6 scale (range) 3.3 (1-4) 
   High, median score on 1-6 scale (range) 5.1 (4.3-6) 
a Educational levels included low = completed no/primary school; intermediate =  
completed lower general secondary education/vocational training; or high =  
completed pre-university education/high vocational training/university.  
One participant (0.3%) filled in ‘other’, without specifying level of education. 
 
 
Interpretation of verbal labels 
Figure 1 shows how verbal labels were interpreted for the two medical 
outcomes. There was a significant effect of outcome on the estimated numerical 
probabilities of verbal labels, that is, participants’ estimates of verbal labels 
were lower for cancer recurrence compared to nausea (F(3.4, 1025.5)=5.21, 
p=0.001). On average, participants’ estimates of verbal labels were an absolute 




Figure 1. Interpretation in percentages of each verbal label (median (1st and 3rd quartile))  
 
Based on our data, we identified those labels that the participants considered to 
reflect a low versus high probability (N=7 vs N=3, respectively; see Figure 1). The 
verbal label ‘regularly’ was excluded as it represented an intermediate 
probability. Low numerate participants tended to estimate higher probabilities 
than high numerate participants for verbal labels indicating a low probability, 
and significantly lower probabilities for verbal labels indicating a high probability 
(F(1.9, 590.6)=7.34, p=0.001). Thus, lower numerate participants discriminated 
less between verbal labels than higher numerate participants. The same 
tendency was seen for educational level and health literacy, but the results were 
not statistically significant (data not shown). There was no significant association 






Our study showed considerable variation in how individuals interpret verbal 
labels that are frequently-used in cancer consultations in which a treatment 
decision needs to be made. Communicating probabilities that are relevant to the 
treatment decision is complex but essential, as probabilities help to weigh the 
potential benefits and harms of treatment. Most people prefer to receive 
probabilistic information numerically, but to use verbal labels to convey a 
probability,18;19 despite recommendations from the literature to avoid the use of 
verbal labels only.20;21 Indeed, in daily clinical practice, radiation oncologists 
frequently use verbal labels only to convey probabilities to patients facing a 
treatment decision.1 Patients’ satisfaction has been shown to be lower when 
receiving probabilistic information verbally, and their interpretation to be less 
accurate.5;22 That is, the magnitude of the probability that an oncologist aims to 
present using a verbal label may not be interpreted as such by the patient. 
Probabilities of common side-effects might be known to clinicians, but clinicians 
should not assume that patients interpret probabilities for different outcomes in 
the same way clinicians do. In fact, in earlier research, we found that patient 
tend to underestimate the probability of a side effect occurring.1 
In line with previous research, we found that the interpretation of verbal 
labels was influenced by the medical outcome, which is likely due to the 
perceived severity and/or the assumed frequency of occurrence of the 
outcomes.6-8 We cannot disentangle the individual effect of perceived severity 
and assumed frequency of occurrence as the outcomes we presented differed 
on both, as is usually the case in actual clinical cases. We further found that less 
numerate individuals estimated numerical probabilities of verbal labels closer to 
50% than more numerate individuals, that is, less numerate individuals tended 
to differentiate less between the verbal labels. This finding is consistent with 
research outside of the medical field,10 and might reflect an “I don’t know” 
response. However, since we do not have a ‘golden standard’ for the 
interpretation of verbal labels, we cannot make any statements on whether the 
high versus low numerate group has more accurate estimates of verbal labels. 
We found a similar effect in differentiation between labels for individuals’ 
educational level and health literacy, although not statistically significant.  
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A strength of our study is that we offered participants a list of verbal labels that 
are most frequently used during cancer decision consultations. This enabled us 
to gain insight in how they interpret non-numerical probability statements used 
in daily clinical practice. Furthermore, we were able to assess the influence of 
multiple determinants in a large sample of the adult census population, as 
proxies for newly-diagnosed patients facing a treatment decision. A possible 
limitation is that our participants did not experience the emotions that patients 
do when they are diagnosed with cancer and face treatment. In general, patients 
seem to underestimate the probability of an adverse effect occurring (1). We 
expect that the variation in interpretation will be similar for newly-diagnosed 
cancer patients and the general adult population.  
 
In conclusion, our results show considerable variation in how individuals 
interpret frequently-used verbal labels, with medical outcome and individuals’ 
numeracy as possible determinants. By using verbal labels, oncologists attempt 
to convey a magnitude of the probability that a patient will experience a benefit 
or harm. The large variation in interpretation of verbal labels shows that the 
magnitude that an oncologist aims to present using a verbal label will likely not 
be interpreted as such by individual patients. It is recommended to avoid the 
use of verbal labels only, to minimize misunderstandings and to prevent patients 
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Step 3: Discussing patients’ values 





Considering patient values and 
treatment preferences enhances 
patient involvement in rectal 
cancer treatment decision making 
Marleen Kunneman, Corie AM Marijnen, Monique CM Baas-Thijssen, 
Yvete M van der Linden, Tom Rozema, Karin Muler, Elisabeth D 
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Background: The shared decision making (SDM) model states that patients’ 
values and preferences should be clarified to choose a strategy that best fits the 
patient. This study aimed to assess whether values and preferences of rectal 
cancer patients are voiced and considered in deciding about preoperative 
radiotherapy (PRT), and whether this makes patients feel more involved in 
treatment decision making. 
Methods: Pre-treatment consultations of radiation oncologists and patients 
eligible for PRT were audiotaped (N=90). Tapes were transcribed and coded to 
identify patients’ values and treatment preferences. Patients filled in a post-
consultation questionnaire on their perceived involvement in decision making 
(N=60). 
Results: Patients’ values were voiced for 62/611 of benefits/harms addressed 
(10%), in 38/90 consultations (42%; maximum 4 values per consultation), and 
most often related to major long-term treatment outcomes. Patients’ treatment 
preferences were discussed in 20/90 consultations (22%). In 16/90 
consultations (18%), the oncologists explicitly indicated to consider patients’ 
values or preferences. Patients perceived a significant more active role in 
decision making if their values or preferences had been voiced or considered. 
Conclusions: Patients’ values and treatment preferences are voiced or 
considered in a minority of consultations. If they are, this increases patients’ 





Shared decision making (SDM) in the clinical encounter has become increasingly 
important in modern health care, both from an ethical and a clinical point of 
view.1;2 Applying the principles of SDM is especially relevant when treatment 
decisions are preference-sensitive, i.e. in the absence of a ‘best choice’ from a 
clinical perspective or when individual patients’ valuation of benefits and harms 
may strongly vary.3-5 One such preference-sensitive decision is the decision 
about short-course preoperative radiotherapy (PRT) in the treatment of patients 
with localized rectal cancer.6 The beneficial effect of PRT on local control, 
compared to surgery only, has been clearly demonstrated, but PRT does not 
convey an additional overall survival benefit.7 Moreover, PRT is associated with a 
higher risk of adverse effects, the most important of which are faecal 
incontinence and sexual dysfunction.8;9 Research has shown great variation in 
how individual patients value possible benefits and harms of PRT and these 
valuations are not consistently related to patient characteristics.10;11 Moreover, 
it turns out to be difficult for clinicians to accurately judge patients’ values for 
health outcomes or patients’ treatment preferences.10;12;13 Patients should 
therefore explicitly voice their values and treatment preferences during the 
consultation with their radiation oncologist, so that these can be considered in 
choosing a treatment strategy that best fits the patient. Most SDM models state 
that clinicians should elicit patients’ values and preferences in treatment 
decision making,2;14;15 but little research has been conducted on whether this 
actually happens in daily clinical practice.16;17 
 
This study aimed to assess 1) the extent to which patients’ values regarding 
benefits and harms of PRT and patients’ treatment preferences are voiced 
during decision consultations about PRT for rectal cancer, 2) if these values and 
preferences are explicitly considered in deciding about treatment, and 3) 
whether patients feel more involved in treatment decision making when their 







This study was conducted in six of the 21 radiotherapy centers in the 
Netherlands in the context of a large multicenter study on communication and 
treatment decision making during decision consultations on PRT for rectal 
cancer.18 All patients eligible for short-course PRT followed by a low-anterior 
resection (sphincter-saving operation) were eligible for inclusion. 
All radiation oncologists working in one of these centers and treating patients 
with rectal cancer were asked to participate. 
 
Procedure 
First consultations, usually the only consultation prior to the start of the 
treatment, of participating radiation oncologists with consecutive eligible rectal 
cancer patients were audiotaped. Participating patients signed an informed 
consent form and completed a questionnaire to assess socio-demographic 
details prior to the consultation. Patients were also asked to fill in a 
questionnaire within one week after the consultation, to assess their perceived 
involvement in treatment decision making. Patients who filled in the post-
consultation questionnaire more than 14 days after the consultation were 
excluded from the analyses (N=5). Radiation oncologists were asked to fill in a 
questionnaire assessing their socio-demographic and work-related details at the 
start of the study. 








Audiotapes of the consultations were transcribed verbatim and coded using an 
adapted version of the ACEPP (Assessing Communication about Evidence and 
Patient Preferences) coding scheme.19 By using this coding scheme, all 
utterances on patient values concerning health-related benefits and harms of 
treatment and on patients’ treatment preferences were identified. We 
considered all patient statements on the importance of a specific benefit/harm 
or on the implication of a benefit/harm for the patient’s everyday life as patient 
values (e.g., “that’s my biggest fear, that something will change in that area” 
(sexual dysfunction); “I'm not someone who finds sex very important, not at my 
age” (erectile dysfunction); “if I become incontinent, than I won’t be able to go to 
concerts anymore” (long-term faecal incontinence); “I don’t want to live in 
constant fear of it coming back” (local recurrence)). All statements containing an 
opinion of the patient regarding possible treatment strategies were considered 
as a treatment preference (e.g., “I want the radiotherapy anyway”; “I think we 
must seize all opportunities to prevent it coming back”; “I  actually  don’t favour 
undergoing  the radiation, I find the risks too great and the benefit too limited”). 
If a patient consented with the treatment that the oncologist proposed without 
any further comment or opinion (Oncologist: “so, let’s do this?”, Patient: “yes”), 
this was not considered as a treatment preference. Utterances of patients’ 
companions were coded as the patient’s, unless the patient contradicted the 
statements. 
First, we coded per benefit or harm addressed whether patients voiced a 
value (yes/no) and who initiated the matter (oncologist/patient). Second, we 
coded whether patients made any explicit comments about their treatment 
preferences (yes/no). Finally, we coded whether oncologists explicitly indicated 
to consider patients’ values and/or treatment preferences in deciding about 
treatment (e.g. “you have to think about this, it’s a difficult choice, everybody 
weighs these outcomes differently”, yes/no), regardless of whether the patient 
actually voiced a value or treatment preference. 
Two raters independently coded the same 10 (11% of total number) 
audiotapes. Inter-rater agreement was substantial (Cohen’s K =0.88) 20. The 
remaining tapes were coded by either one of the two raters (intra-rater 
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agreement based on eight (9%) tapes per rater coded twice with a time 
difference of 19 months, Cohen’s K =0.67 and 0.87). 
In the post-consultation questionnaire, we assessed patients’ perceived 
decisional role using a modified version of the Control Preferences Scale (CPS), 
in which participants were asked to select one of five statements on decisional 
role.21;22 The roles ranged from (A) I made the decision about PRT alone, through 
(B) I made the decision about PRT after considering my radiation oncologist’s 
opinion, (C) my radiation oncologist and I made the decision about PRT together, 
(D) my radiation oncologist made the decision about PRT after considering my 
opinion, to (E) my radiation oncologist made the decision about PRT alone. 
 
Statistical analyses 
Descriptive statistics were used to report patients’ and oncologists’ 
characteristics, and the number of values and preferences discussed. The 
number of values discussed was compared by patients’ age, gender, being 
accompanied by a companion during the consultation and patients’ educational 
level with Spearman correlations, Mann-Whitney U-tests, and Kruskal-Wallis 
tests. The discussion of treatment preferences (yes/no) was compared by 
patients’ age, gender, being accompanied during the consultation and patients’ 
educational level with Chi-square tests and Kruskal-Wallis tests, as applicable. 
CPS-scores were compared by the discussion of values or preferences (yes/no) 
and the explicit consideration of values or treatment preferences (yes/no) with 




We approached 128 eligible patients, all diagnosed between November 2010 
and April 2014. Twelve patients (9%) could not be reached and twenty-one 
(17%) refused to participate. Ninety-five patients (74%) agreed to have their 
consultation audiotaped. Five of them were excluded from the analyses because 
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of incomplete audiotaping. Of the remaining 90 patients, 60 (67%) completed 
the post-consultation questionnaire, a median of four days after the consultation 
(range, 0-13). No significant differences were found for patients’ age, gender, or 
educational level between those who did versus did not complete the post-
consultation questionnaire. All 21 radiation oncologists approached agreed to 
participate and audiotaped a median of four consultations (range, 1-11). In 
Table 1 participant demographic and work-related (radiation oncologists) 
characteristics are listed. 
 
Table 1. Participant characteristics 
 N (%) 
Patients (N=90)  
Mean age, years ± s.d. (range) 64 ± 10.1 (40-87) 
Male gender 66 (73) 
Educational level a  
   Low 17 (33) 
   Intermediate 32 (44) 
   High 26 (22) 
Companion present at consultation 80 (89) 
Perceived decisional role b  
   Patient made the decision   4 (7) 
   Patient made the decision after considering the radiation oncologist’s  
   opinion 
  13 (22) 
   Radiation oncologist and patient made the decision together   22 (37) 
   Radiation oncologist made the decision after considering the patient’s  
   opinion 
  12 (20) 
   Radiation oncologist made the decision     9 (15) 
  
Radiation oncologists (N=21)  
Mean age, years ± s.d. (range) 40 ± 6.5 (27-52) 
Male gender   6 (29)c 
Median time since specialization, years (range) 6 (0-20) 
Median number of rectal cancer patients per month (range) 3 (1-8) 
a Educational levels included low = completed no/primary school; intermediate = completed lower 
general secondary education/vocational training; or high = completed pre-university education/high 
vocational training/university. Eighteen patients did not respond to this question.  
b As assessed in the post-consultation questionnaire, filled in by N=60 patients. 





Oncologists and patients discussed patients’ values in 29/90 consultations 
(32%), patients’ treatment preferences in 11/90 consultations (12%), or both in 
9/90 consultations (10%). In the other 41/90 consultations (46%), neither 
patient’s values, nor their treatment preferences were addressed. 
Per consultation, a median of seven benefits and harms of PRT were 
addressed (range, 2-12), summing up to in total 611 discussions on benefits 
and harms in the 90 consultations. Patients’ values concerning these benefits 
and harms were voiced in 62/611 cases (10%), in 38/90 consultations (42%, 
maximum of 4 values per consultation). Values most often related to sexual 
dysfunction (N=30/62, 48%, e.g., erectile dysfunction or ejaculation disorder 
(men), vaginal dryness (women) or sexual problems in general), long-term faecal 
incontinence (N=12/62, 19%), and local control (N=8/62, 13%) (Figure 1). Of 
these 62 discussions on patient values, three (5%) were initiated by the 
radiation oncologist, all concerning erectile dysfunction in male patients, for 
example by inviting patients to express their opinion on a harm (see Figure 1). 
The patients initiated all other discussions.  
 Patients’ treatment preferences were discussed in 20/90 consultations 
(22%). In 15 of these 20 cases (79%), patients expressed a preference to 
undergo PRT, in the other five cases (21%) patients expressed a preference to 
forego PRT.  
There was no significant association between the number of values 
discussed or whether or not treatment preferences were discussed, and 






Figure 1. Percentage of times that a patient’s value relating to benefits/harms of PRT was voiced, 
and initiative. 
Abbreviations: ST = short term; LT = long term. Note: The total length of the bars per benefit/harm 
represents the percentage of consultations in which the benefit/harm was addressed. *As 
percentage of consultations with patients from relevant patient group (male/female patients).  
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Values voiced at the patient's initiative




In deciding about PRT, the radiation oncologists explicitly indicated to consider 
patients’ values in 1/90 consultations (1%), patients’ treatment preferences in 
10/90 consultations (11%), or both in 5/90 consultations (6%). 
Of the consultations in which patients’ values or treatment preferences were 
discussed, the oncologist also explicitly indicated to consider these in treatment 
decision making in 4/38 and 6/20 cases (11% and 30%), respectively. In the 
one consultation in which the voiced value was explicitly considered in decision 
making, the oncologist indicated that the patient’s treatment preference was of 
importance as well. In this case, the patient indicated that he needed more time 
to form a preference and a second consultation was scheduled. 
In addition, there were seven consultations in which the oncologists 
indicated that they wanted to consider the patient’s treatment preference, but 
the patient did not voice any. In five of these consultations, the oncologist 
recommended PRT and the patient consented. In the other two consultations, 
the decision was postponed and the oncologist and the patient agreed to a 
follow-up appointment by telephone. 
 
Patients’ perceived role in deciding about PRT is shown in Table 1. Overall, 
patients perceived they had a significantly more active role in deciding about 
PRT (lower CPS-score) when they had voiced more values (rho=-0.33, p<0.01), 
or when they had put forward their treatment preference to their radiation 
oncologist (U=214, z=-2.8, p<0.01). Patients also perceived they had a 
significantly more active role when the oncologist had indicated to consider the 
patient’s values or preferences in deciding about PRT, compared to when the 










The SDM model states that after informing patients on possible treatment 
options, possible benefits and harms and their respective probabilities, patients’ 
values and preferences should be clarified or elicited in the decision making 
process.2;14;15 
The first aim of this study was to assess the extent to which rectal cancer 
patients voice their values regarding benefits and harms of PRT and their 
treatment preferences during decision consultations. In less than half of the 
consultations, patients expressed one or more values. In total, patients 
expressed their values regarding only a small portion of all benefits and harms 
of PRT discussed; and in almost all cases at their own initiative. If patients 
explicitly voiced their values, these most often concerned long-term major 
outcomes of PRT, such as local recurrence, fecal incontinence, or sexual 
dysfunction. This is consistent with previous research in which we showed that 
rectal cancer patients as well as radiation oncologists consider these outcomes 
important, and necessary to address during this consultation.23 Patients’ 
treatment preferences were discussed in about one out of five consultations. 
The literature shows that overall, rectal cancer patients require only a small 
beneficial effect of PRT to consider it worthwhile, but large variation exists in 
individual treatment preferences,10 and it is difficult for clinicians to predict 
patients’ values or preferences.10;24 Therefore, we must be alert to the ‘silent 
misdiagnosis’ of patients’ values and treatment preferences.24 After providing 
patients with all relevant information, oncologists can invite patients to share 
their ideas, concerns and expectations. Although this has been recommended in 
the literature,25 research shows that in daily clinical practice, this only happens 
in limited extent.17 Only after discussing and understanding how the patient 
values trade-offs between benefits and harms of treatment, can the radiation 
oncologist recommend a strategy that best fits the patient.  
The second aim of the study was to assess the explicit consideration of 
patients’ values and treatment preferences in treatment decision making. In 
less than one out of five consultations, the radiation oncologists explicitly 
indicated to consider the patient’s values or treatment preferences in deciding 
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about PRT. It is noteworthy that in seven consultations, the oncologist stated 
that the patient’s treatment preference was of importance in deciding about 
treatment, but the patient did not voice a preference and the oncologist did not 
probe any further. In an earlier study, we showed that radiation and medical 
oncologists rarely express to their patients, as a reason for the encounter, that a 
treatment decision needs to be made.26 Many patients might not realize that 
foregoing (neo-)adjuvant treatment is a viable option and that their values and 
treatment preferences are of importance in the treatment decision. Therefore, a 
statement from the oncologist that the patient’s values and treatment 
preferences are to be considered might take patients by surprise. Patients may 
need more encouragement from the oncologist, or, as some patients in our 
study indicated, more time to form and express their values and treatment 
preferences. When facing a preference-sensitive health-related decision, time 
pressure should not be at stake and individuals should be able to take at least 
days before committing to an option.27 
The last aim of this study was to assess whether patients feel more involved 
in treatment decisions when their values or treatment preferences are voiced or 
considered. Most patients felt they had shared the decision with their radiation 
oncologist at least to some extent, but the results showed that they perceived a 
more active role when their values or preferences had been addressed during 
the consultation, or when the oncologist indicated to consider the patient’s 
values or preferences in the decision making process. Our findings are 
consistent with theoretical models on SDM.2;14;15;24 Discussing and explicitly 
considering patients’ values and preferences will thus not only help choosing 
what is best for the patient, it will also make patients feel more involved in the 
treatment decision, which has been shown to lead to better patient outcomes.28 
As can be seen from a number of recent publications, the interest in the 
possible harms of rectal cancer treatment, and of other cancer treatments as 
well, is rising.29;30 Our study is thus timely in showing the importance of 






A strength of our study is that by audiotaping the consultations, we were able to 
observe the actual communication between radiation oncologists and patients 
and did not depend on radiation oncologists’ or patients’ recall. Our study also 
has limitations. First, we only examined verbal communication. We found that 
almost all values were voiced at the initiative of the patient, but we do not have 
information on whether the radiation oncologists gave non-verbal cues to 
patients to express their opinion. Second, because of relatively small numbers of 
patients included per radiation oncologist, we were unable to assess 
associations between the variation in values and treatment preferences 
addressed and oncologists’ characteristics.  
It is noteworthy that participating patients and radiation oncologists were 
informed on the overall aims of the study. If they were actually aware of our aims 
to assess the communication on benefits and harms of PRT, and the patient’s 
role in deciding about treatment at the time of the consultation, than our 
findings most probably are overestimations of the number of times that patients’ 
values and treatment preferences are discussed in daily clinical practice. 
In recent years, there has been interest in the value of so-called values 
clarification methods to give patients insight in how they value benefits and 
harms of treatment.31 In a follow-up study, we offer rectal cancer patients such a 
tool prior to their consultation with the radiation oncologist,32 and will evaluate 
the effect of the tool on the communication about patients’ values and on 
patients’ participation in the decision-making process.  
 
In conclusion, our study shows that rectal cancer patients’ values and treatment 
preferences regarding PRT are voiced or considered in a minority of 
consultations in which a treatment decision needs to be made. Discussing or 
considering values or preferences enhances patients’ perceived involvement in 
the treatment decision. This brings empirical support to the SDM model that 
states that after providing patients with relevant information, patients’ values 
and preferences should be clarified or elicited before choosing a treatment that 
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Background: Vaginal brachytherapy (VBT) in high-intermediate risk endometrial 
cancer (EC) provides a significant reduction in the risk of local cancer 
recurrence, but without survival benefit and with increased mucosal atrophy. 
Five-year local control is estimated to be similar for VBT and a watchful waiting 
policy (WWP), in which patient receive VBT combined with external radiation in 
case of a recurrence. Our aim was to assess treatment preferences of EC 
patients and clinicians regarding VBT and WWP, and to evaluate their preferred 
and perceived involvement in treatment decision making.  
Methods: Interviews were held with 95 treated EC patients. The Treatment 
Trade-off Method was used to assess minimally-desired benefit from VBT in local 
control. Patients’ preferred and perceived involvement in decision making were 
assessed using a questionnaire. Seventy-seven clinicians completed a 
questionnaire assessing their minimally-desired benefit and preferred 
involvement in decision making. 
Results: Minimally-desired benefit of VBT was significantly lower for patients 
than for clinicians (median=0 vs 8%, p<0.001), for irradiated than for non-
irradiated patients (median=0 vs 6.5%, p<0.001), and for radiation oncologists 
than for gynecologists (median=4 vs 12%, p<0.001). Substantial variation 
existed within the groups of patients and clinicians. Participants preferred the 
patient and clinician to share in the decision about VBT. However, irradiated 
patients indicated low perceived involvement in actual treatment decision 
making.  
Conclusion: We found variation between and within patients and clinicians in 
minimally-desired benefit from VBT. However, the recurrence risk at which 
patients preferred VBT was low. Our results showed that patients consider active 





Endometrial cancer (EC) is the most common gynecological malignancy in 
western countries, with an incidence of 15-25 per 100,000 women per year.1 In 
most cases primary treatment consists of total hysterectomy and salpingo-
oophorectomy. Several randomized trials have established the role of 
radiotherapy in high-intermediate risk EC.2-4 Vaginal brachytherapy (VBT) 
provides a highly significant reduction in the risk of vaginal cancer recurrence 
(with freedom from local cancer recurrence, from now on termed ‘local control’), 
but without survival benefit.5 However, VBT is associated with side effects such 
as mucosal atrophy.5;6 An alternative to standard postoperative VBT could be a 
watchful waiting policy (WWP), in which patients are treated with radiotherapy 
only if they develop a vaginal relapse. The ultimate five-year local control 
including treatment for relapse is estimated to be similar for VBT and WWP.7 
However, treatment of a vaginal relapse is more intensive, as it consists of both 
External beam radiotherapy (EBRT) and VBT. With WWP, about 86% of EC 
patients will remain disease-free and will not require radiotherapy at all.7 
Therefore, the question remains if upfront treatment with VBT for all EC patients 
with high-intermediate risk factors or WWP should be preferred. This question is 
the rationale of the fourth Post-Operative Radiation Therapy in Endometrial 
Carcinoma (PORTEC-4) trial, in which a watchful waiting policy is randomly 
compared to VBT.8 
 
No studies have been done on preferences of EC patients’ and clinicians’ 
preferences with regard to treatment strategies and treatment outcomes, 
despite the potential benefits of VBT not necessarily outweighing its potential 
side-effects. At the same time, WWP can be perceived as ‘doing nothing’. 
Research has shown that cancer patients feel that ‘doing nothing’ is no choice, 
and experience considerable pressure, also from family members and doctors, 
to seek active treatment.9-11 Most studies on preferences in other cancer 
settings have reported on situations where the benefit of active treatment is 
larger than foregoing treatment. In the present case though, the ultimate five-
year local control is estimated to be very high and similar for both treatment 
strategies. 
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We expect individual patients to value treatment strategies and outcomes 
very differently, and thus, the treatment decision seems highly suitable for 
involving patients.12;13 Involving patients in decision making facilitates 
incorporating their preferences in treatment decisions.14 This is especially 
relevant since preferences are difficult to predict based on socio-demographic 
factors or disease characteristics,15;16 and patients and clinicians repeatedly 
have been shown to value treatment outcomes differently.14;17;18 Research has 
shown that patients are willing to accept a higher chance of local recurrence to 
improve functional outcomes of treatments.19-22 Clinicians tend to 
underestimate patients’ preference for less toxic treatments, as well as their 
preferred involvement in decision making.18;19  
 
The aim of this study was to assess minimally-desired benefit from VBT, in terms 
of local control and compared to WWP,  of EC patients and treating clinicians 
(radiation oncologists and gynecologists). Also, patients’ preferred and perceived 
roles in treatment decision making were examined, as well as clinicians’ 
decisional role preferences. 
 
Materials and Methods 
 
Study population – patients and clinicians 
Participants were EC patients, randomly selected from hospital databases and 
approached via their treating clinician. Selection criteria were: having undergone 
surgery with or without VBT between 2007 and 2013, aged under 90 years, and 
having no history of other malignancies. We aimed to include 100 EC patients, 
half of whom had been treated with surgery alone (low risk EC), and half with 
surgery followed by VBT (high-intermediate risk EC). 
For the clinician study, we approached all 198 clinicians of the Dutch 




Individual face-to-face interviews were held with each patient to assess 
minimally-desired benefit from VBT. Five interviewers were trained and adhered 
to a strict interview script. Socio-demographic details, medical history, and 
preferred and perceived involvement in decision making were assessed by self-
report questionnaire in the weeks before the interview. Clinicians were asked to 
fill out a web-based questionnaire in which their treatment preferences, socio-
demographic factors and work-related details and attitudes towards treatment 
decision making were assessed. The Medical Ethics Committee of Leiden 
University Medical Center approved the study. 
 
Measures 
Patients’ minimally-desired absolute benefit from VBT, in terms of five-year local 
control and compared to WWP, was assessed face-to-face using the Treatment 
Tradeoff Method (TTM).23 Patients were asked to imagine that they had recently 
been diagnosed with EC and that their clinician offered them two treatment 
strategies. We made explicit that the situation was hypothetical and did not refer 
to their situation. After sequentially offering the information on the TTM board 
(Figure 1), we started with presenting a 14% risk of cancer recurrence at five 
years for treatment A (surgery alone) and a 2% risk of cancer recurrence for 
treatment B (surgery and VBT). We then asked patients to weigh recurrence rate, 
side effects and burden of treatments and to indicate which treatment strategy 
they preferred at this 12% benefit of treatment B. Next, the probability of local 
recurrence after surgery alone was varied systematically and patients were 
asked each time which treatment they preferred. Patients’ minimally-desired 
benefit (recurrence rate with WWP minus the 2% recurrence rate after VBT) was 
searched by bracketing the recurrence rate either within the range of 2 to 14 out 
of 100, (if their initial preference was treatment B: surgery and VBT, indicating 
that they required a benefit of 12% or less) or within the range of 15 to 100 out 
of 100 (if their initial preference was treatment A: surgery alone, indicating that 
they required more than 12% benefit). For example, when a patient indicated 
that she preferred treatment B at a 12% benefit, we then presented a probability 
of local recurrence after surgery alone of 2% (no benefit of treatment) and asked 
which treatment she would prefer. If she indicated to prefer treatment A, we 
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then presented a probability of local recurrence after surgery alone of 8% (6% 
benefit of treatment) and again asked which treatment she would prefer. The 
probability of local recurrence after surgery alone was varied until patients’ 
minimally-desired benefit was reached. We built in a check for understanding in 
patients preferring VBT for no additional benefit by lowering the recurrence rate 
after surgery alone to 0% (a 2% disadvantage of VBT).  
We pilot-tested a self-administered format of the TTM in 10 treated EC 
patients. Patients evaluated this format to be too difficult because of the high 
amount of (new) medical information. We therefore decided to use the 
traditional face-to-face format for the TTM in patients. Clinicians were offered 
the TTM as part of an online questionnaire. Instead of sequentially offering the 
information, all information was given to them at once. Clinicians were asked at 
which minimally-desired absolute benefit of VBT they would prefer VBT, and 
recurrence rate was not systematically varied. 
We assessed patients’ and clinicians’ preferred decisional role using a 
modified version of the Control Preferences Scale (CPS), in which participants 
were asked to select one of five statements on roles in treatment decision 
making.24;25 The roles ranged from (A) the patient makes the decision about VBT 
alone, through (C) the patient makes the decision together with the clinician, to 
(E) the clinician makes the decision on VBT alone. 
Irradiated patients had actually faced the decision whether or not to undergo 
radiation. We explored to what extent they felt they had been involved in this 
decision by asking them: To what extent did you have space to 1) think about 
benefits and harms of VBT, 2) give your opinion on the benefits and harms of 
VBT, and 3) participate in decision making to your preferred extent. They could 
respond to each question using a score between 1 (not at all) to 7 (a lot). Finally, 
we asked: Do you feel you had a choice in the decision about whether or not to 
undergo VBT? Responses could be negative, affirmative or ‘I don’t know’. 
Both patients’ and clinicians’ questionnaire contained additional questions 





Figure 1. Information presented in the TTM on treatment options. The numbers in the margin 
represent the order in which the board was built up. The initially offered figures for surgery only were 
86 out of 100 women having no recurrence, 14 having recurrence, thus implying a 12% benefit of 
VBT compared to WWP. The light grey boxes represent potential side effects of VBT, dark grey 
represent potential side effects of EBRT. 
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Statistical analysis 
Descriptive statistics were used to describe participant characteristics and  
minimally-desired benefit from VBT (TTM). Preferred benefit scores were not 
normally distributed, so we present medians and compared between groups 
with Mann-Whitney U tests. Using χ2 tests, patients and clinicians were 
compared on decisional role preferences (CPS) and perceived involvement, after 
subdivision into two categories by merging response categories 1-3 and 5-7. 





In total, 140 eligible patients, treated between 2007 and 2013, were 
approached. Of these patients, 95 (68%) were interviewed and completed the 
questionnaire. Of the 198 clinicians approached, 77 (39%; 52 gynecologists, 
response rate 32%; 25 radiation oncologists, response rate 69%) completed the 
online questionnaire including the TTM. In Table 1 participant demographic 
characteristics, and treatment (patients) and work-related (clinicians) 
characteristics are listed.  
 
Treatment preference and minimally-desired benefit from VBT 
In Table 2 minimally-desired benefit from VBT in terms of local control and 
compared to WWP is listed. Figure 2 shows the cumulative proportion of 
participants preferring VBT according to minimum benefit. Overall, minimally-
desired benefit was significantly lower for patients than for clinicians (median=0 
vs 8%, U=1709, z=-5.8, p<.001). Irradiated patients required a significantly 
lower benefit than non-irradiated patients (median=0 vs 6.5%, U=509, z=-5.08, 
p<.001). There was no significant association between minimally-desired benefit 
from VBT and patients’ age, educational level, having a partner or children, or 
co-morbidity. Minimally-desired benefit was significantly lower for radiation 
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oncologists than for gynecologists (median=4 vs 13%, U=293, z=-3.2, p=.001). 
There was no significant association between minimally-desired benefit from 
VBT and clinicians’ age, gender, institution (academic/non-academic), years 
since specialization or number of EC patients treated per year. 
 
Table 1. Participant characteristics 
 N (%) 
Patients (N=95)  
   Median age, years (range) 68 (46-90) 
   Median time since diagnosis, months (range) 6 (1-62) 
   Treatment  
      Surgery 42 (44) 
      Surgery + radiotherapy 53 (56) 
   Number (none or 1) of co-morbidities 46 (50) 
   Partner (yes) 71 (75) 
   Children (yes) 75 (79) 
   Educational level a  
      Low 41 (46) 
      Intermediate 28 (31) 
      High 20 (23) 
   Region of inclusion (Leiden) 54 (57) 
  
Clinicians (N=77)  
   Specialty  
      Radiation oncology 25 (33) 
      Gynecologic oncology 24 (31) 
      Gynecology (focus on oncology) 28 (36) 
   Median age, years (range) 48 (33-65) 
   Median time since specialization, years (range) 10 (0-36) 
   Median number of EC patients per year (range) 20 (0-70) 
   Male gender 31 (40) 
   Current institution (academic) 27 (35) 
a Educational levels included low = completed no/primary school, intermediate = completed lower 
general secondary education/vocational training; or high = completed pre-university education/high 





Table 2. Minimally-desired benefit in local control from VBT 
 Median desired 
benefit 
Range Preferring VBT at 
0% benefit 
Patients (N=95)    
   Irradiated   0% 0-  49% 42 (79%) 
   Non-irradiated   6% 0-100% 14 (33%) 
    
Clinicians (N=77)    
   Radiation oncologists   4% 0-  23%   1 (4%) 
   Gynecologic oncologists   8% 0-  49%  0 (0%) 
   Gynecologists 17% 3-  48%   1 (4%) 




Figure 2. Cumulative proportion of participants preferring VBT over WWP according to minimum 
percentage of benefit in local control. Numbers of non-irradiated patients do not add up to 100% 







Figure 3 depicts the patients’ and clinicians’ preferences regarding their role in 
the decision about VBT in the treatment of EC. No significant associations were 
found between decisional role preferences and patients’ treatment, age, 
educational level, having a partner or children, or co-morbidity. Clinicians who 
had specialized more recently had a stronger preference for a more active 
clinician’s role in deciding about VBT (χ2=6.87, p < 0.05). No significant 
associations were found between decisional role preferences and clinicians’ 
age, gender, specialization, institution (academic/non-academic), or number of 
EC patients treated per year. 
 
 
Figure 3. Patients’ (N=94) and clinicians’ (N=77) decisional role preferences in deciding about VBT.  
 
Perceived actual involvement in decision making about VBT 
A majority of irradiated patients indicated that they had lacked space to think 
about benefits and harms of VBT (42%), give their opinion on these benefits and 
harms (43%) or participate in decision-making to their preferred extent (45%), 
with a high within-subject overlap between the responses to the three questions. 
Older patients (≥68) more often indicated not to have been involved in the 
decision to their preferred extent (χ2= 7.37, p < 0.05). Otherwise, there were no 
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significant associations between perceived involvement and patients’ time since 
diagnosis, educational level, having a partner or children, or co-morbidity.  
A total of 44% of irradiated patients indicated they felt they had had no 
choice regarding  VBT. There were no significant associations between whether 
patients felt they had had a choice and patients’ age, educational level, having a 




This study had a dual objective. Firstly, to assess patients’ and clinicians’ 
minimally-desired benefit  from VBT, in terms of local control (defined as 
freedom from local cancer recurrence at 5 years) and compared to WWP. 
Secondly, to assess patients’ and clinicians’ preferred involvement in this 
decision, as well as perceived actual involvement in this decision of irradiated 
EC patients. 
Our study showed considerable variation between, as well as within, patients 
and clinicians in their minimally-desired benefit from VBT compared to WWP. 
Patients preferred VBT at a lower minimal benefit than clinicians. Furthermore, 
irradiated patients and radiation oncologists preferred VBT at a lower minimal 
benefit than, respectively, non-irradiated patients and gynaecologists. The 
variation within groups could not be explained by socio-demographic factors or 
work-related characteristics. The difference in minimally-desired benefit between 
clinicians from different specialties has also been shown in earlier research, with 
clinicians generally requiring less benefit from the treatment of their 
specialty.26;27 Because patients highly value clinicians’ recommendations, these 
can lead patients to make or agree with decisions that go against what they 
would otherwise prefer.28;29 The importance of clinicians’ recommendations and 
the substantial variance in both patients’ and clinicians’ treatment preferences 
highlight the need for involving EC patients in decisions about VBT.  
Overall, most patients preferred VBT at a low benefit in local control, 
although the ultimate five-year local control is estimated to be similar for both 
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treatment strategies. Choosing VBT despite no benefit in five-year local control is 
possibly explained by patients preferring to seek active treatment,9 and seeking 
to be assured of being disease-free sooner. Another explanation could be that 
patients want to make sure they have done everything possible, as opposed to 
‘doing nothing’.10 Furthermore, patients might consider possible side effects of 
VBT as relatively mild, compared to possible side effects of EBRT. 
 Two clinicians (8%) and 56 patients (59% of total; 79% of irradiated patients) 
indicated to choose VBT at no additional benefit. We assumed their answers 
implied a strong preference for VBT or ‘active treatment’ rather than as 
indication of misunderstanding. Because deleting them would bias the 
minimally-desired benefit upwards, we decided against removing them from the 
analysis. This preference of treatment despite no benefit is a seemingly non-
rational answer and has been found in earlier studies, especially amongst 
irradiated patients.14;30 It is possibly caused by anticipated regret and a wish to 
of have done everything one could. Another possible explanation is positive 
experiences with VBT and post hoc justification. The latter implies that patients 
may have a desire to justify the prior decision as being the correct one.30 In 
particular, none of these included patients had experienced a relapse and they 
could have assumed that this was a result of VBT. 
The large majority of patients and clinicians preferred both the patient and 
clinician to share in the decision about VBT. However, individual differences 
occur in the interpretation of sharing decisions, which may range from receiving 
information or assent to a treatment recommendation to actively deciding on 
treatment.31;32 Clinicians should be aware of patients’ wish to participate in 
treatment decisions and involve them as much as possible to the patient’s 
preferred extent.  
A possible limitation of this study is the different methods used in assessing 
minimally-desired benefit in the patient versus clinician group. We intended to 
measure minimally-desired benefit in a direct way through an online 
questionnaire in both groups. However, after pilot-testing the self-report 
questionnaire, we concluded that this method was not feasible for participants 
unfamiliar with the complicated medical information. Patients as well as 
clinicians evaluated the methods used as clear (data not shown). Another 
possible limitation is that patients in our study had already started or finished 
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their treatment. Due to logistical reasons, we were unable to include patients at 
the moment they were actually facing this treatment decision. 
In the PORTEC-4 trial, a postoperative WWP is compared with standard VBT 
in a randomized clinical trial.8 This study will provide data on overall side effects 
and quality of life of treated EC patients. Furthermore, results will show whether 
the exact relapse rate after WWP is indeed around 14%, and whether the five-
year local control, including treatment for relapse, is indeed similar for both 
treatment strategies. Our study shows that for a benefit of 12%, over 90% of 
radiation oncologists, but less than 50% of gynecologists would recommend 
VBT, while most of the patients would prefer VBT. Clinicians should be aware of 
this variation and be transparent to their colleagues and patients on their 
considerations to recommend one or the other treatment strategy. 
 
In conclusion, our results showed a considerable variation between, as well as 
within, patients and clinicians in how they value local control, harms, and burden 
of treatment. We recommend that clinicians inform patients on the benefits and 
harms of treatment strategies, elicit patients’ preferences and consider these 
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With the rapid advances in the field of medicine, more and more treatment 
strategies can become available for the same condition – making decision 
making more complex. Involving patients in a shared decision making (SDM) 
process is increasingly the preferred approach to making healthcare decisions 
when more than one reasonable option is available.1-3 These decisions are 
called ‘preference-sensitive’.4;5 Examples include decisions about (neo-)adjuvant 
cancer treatments. Foregoing these treatments is often a clinically viable 
option,6-8 making the involvement of patients in selecting the best treatment 
strategy crucial.  
There are several arguments for following the principles of SDM. SDM is 
associated with improved patient satisfaction, lowered anxiety and decisional 
conflict and may improve quality of life and reduce physical complaints.9-11 Also, 
SDM may reduce unwarranted practice variation, and by that, possibly reduces 
health care costs and waste as well.12-14 Evidence on costs and cost-
effectiveness is equivocal,15-17 and advocates of SDM argue that costs should 
not overshadow the underlying principles of SDM. The main imperative for SDM 
“must rest on the principles of good clinical practice, respecting patients’ right to 
know. Patients’ informed preferences should be the basis for professional 
actions”.18 In the Netherlands, the importance of patient involvement in 
treatment decision making is acknowledged by the minister of Health, Welfare 
and Sport, Edith Schippers.19 Indeed, the legislation (Medical Treatment 
Agreements Act, WGBO) states that healthcare providers are obligated to inform 
patients on possible treatment strategies, in writing if desired by the patient.20  
Still, some question the feasibility of SDM in daily clinical practice, and claim 
that SDM fails to acknowledge the imbalance in knowledge and power between 
the clinician and the patient.21;22 Time constraints, patients’ incapability, or 
clinical situation are often cited as barriers for SDM.23;24 Indeed, in daily clinical 





To accomplish SDM, three key steps need to be followed:  
Step 1:   Creating choice awareness,  
Step 2:   Discussing treatment options in detail, and  
Step 3: Discussing patients’ values and preferences and deciding what is 
best.2;27;28  
 
Taking these three steps as the starting point, our aim was to assess to what 
extent the key steps of SDM are followed in daily clinical practice in preference-
sensitive decisions on (neo-)adjuvant cancer treatment. In this chapter, we give 
an overview of the main findings, and discuss them in relation to the existing 
literature on SDM. Subsequently, recommendations for future research and 
clinical practice are provided. 
 
Step 1. Creating choice awareness 
 
‘Making a treatment decision’ as a reason for the encounter 
The first step in SDM is for both the clinician and the patient to acknowledge 
that there is a decision to be made. This step has received relatively little 
attention in the literature to date,26 even though it is pivotal for SDM.2 Prior 
research found that many patients facing a decision with marked trade-offs 
between benefits and harms were not aware that a treatment decision had to be 
made.29 Oncologists can create choice awareness by explicitly stating that 
making a treatment decision is the reason for the encounter. Our research 
showed that oncologists rarely express this need to make a treatment decision, 
and instead, use the consultation to explain the one treatment strategy they 
have to offer (Chapter 2). By that, oncologists miss a crucial opportunity to 
create choice awareness and to engage patients in the SDM process. Our 
findings align with results from a systematic review by Couët and colleagues.26 
They described studies that used the OPTION instrument, which is used to 
observe the extent to which clinicians involve patients in decision making.26;30 
OPTION is often used to measure SDM, even though the scale only assesses 
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clinicians’ behaviour. Couët found that awareness of treatment choice was 
created in only one in three studies. This is still higher than the 3% that we found 
in our study, which might be due to the differing clinical contexts. The only 
studies that identified the creation of some degree of choice awareness were 
outside the field of oncology. 
 
Creating choice awareness as part of setting an agenda 
Stating a reason for the encounter can be seen as a part of setting an agenda 
for the consultation. Evidence suggests that collaboratively setting an agenda 
increases patient centeredness in various ways – increased patient and clinician 
satisfaction, greater patient empowerment, and more two-way information 
exchange to support individualized treatment decisions.31-33 Collaboratively 
agenda setting, creating choice awareness, and indicating that the patient’s 
views count may help patients realize that multiple treatment strategies are 
available and a decision needs to be made. To date, research on agenda setting 
has mainly been conducted within primary care. In future research, the effects of 
collaboratively setting an agenda and creating choice awareness in the pre-
treatment consultations in specialty care on patients’ satisfaction, 
empowerment, and involvement, and on the extent of two-way information 
exchange should be further explored. 
Appropriately creating choice awareness might be a simple, inexpensive, yet 
effective step in empowering patients to participate in treatment decision 
making. In our study described in Chapter 2, we were unable to assess whether 
an oncologist explicitly mentioning that a treatment decision needs to be made 
is associated with enhanced patient involvement in decision making, given the 
small number of consultations where this occurred. Therefore, in a recent pilot 
study, we offered lay people – as proxies for newly-diagnosed cancer patients – 
reasons for the encounter as stated in daily clinical practice. Results suggest 
that the stated reason for the encounter can have a significant effect on 





Choosing between two treatments versus declining treatment 
The option of foregoing (neo-)adjuvant treatment was not explicitly addressed as 
a viable one in any analysed consultation with rectal or breast cancer patients. 
Earlier research on preference-sensitive treatment decisions has found similar 
results.25;34;35 Alternative options or the option of foregoing treatment may be 
presented only when a patient is not eligible for a certain treatment.36 This 
approach is not concordant with the SDM model or informed consent norms. To 
patients, choosing between two possible treatment strategies – for example 
surgery alone or radiotherapy followed by surgery in rectal cancer – might feel 
less burdensome than declining the one treatment the oncologist has on offer.37 
Therefore, if foregoing (neo-)adjuvant treatment is a viable option, it should 
explicitly be presented as such. 
 
Best timing for creating choice awareness 
Above, we have focused on the pre-treatment consultation as the time point to 
create choice awareness. However, the best timing to create choice awareness 
might be prior to this consultation. During multidisciplinary team meetings, 
almost all patients are discussed and possible treatment strategies are 
identified for each individual. In the case of preoperative radiotherapy for rectal 
cancer, the surgeon discusses the treatment recommendation from the 
multidisciplinary team with the patient.25 To facilitate SDM, clinicians should be 
aware that the recommendation from the multidisciplinary team is not a final 
decision, especially in preference-sensitive decisions – as this would leave little 
to no room for patients’ values and preferences to be considered. Indeed, 
research shows that clinicians mainly focus on medical information exchange 
and rarely discuss patients’ characteristics or preferences in multidisciplinary 
team meetings.38;39 If the recommendation from the team is presented as a final 
decision early on in the healthcare experience, patients may perceive this as the 
'right' treatment and it could be difficult to later create awareness of choice. 
Returning to the case of preoperative radiotherapy in rectal cancer, the surgeon 
could, for example, explicitly indicate that the patient will be referred to a 
radiation oncologist to talk about the preoperative radiotherapy, and the pros 
and cons of this neo-adjuvant treatment. Such statement will help patients 
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realize that there is more than one reasonable option available, and that a 
decision still needs to be made. We must ensure that throughout the whole 
healthcare system, the principles of SDM are followed in making preference-
sensitive decisions in collaboration with the patient. Thus, the first step of SDM 
reaches beyond one consultation; the multidisciplinary team discussion and the 
referring clinician(s) should be part of the process of creating choice awareness 
as well. 
Taking this one step further, the best timing to create choice awareness 
might even be prior to the specialty consultation, namely before becoming a 
patient and entering the healthcare system. Even before individuals experience 
the emotions that accompany a serious diagnosis as cancer, they can be made 
aware that healthcare treatment decisions need to be made and that their views 
count. In the Netherlands, cancer societies (for example ‘KWF 
Kankerbestrijding’), patient advocacy groups (for example ‘Darmkanker 
Nederland’), and the Foundation for Idealistic Advertising (SIRE, Stichting Ideële 
Reclame) may be the best organizations to be involved in such a national 
advertising program. 
 
Creating choice awareness in clinicians 
One reason why oncologists rarely create choice awareness could be that they 
themselves perceive little choice. As we have shown in Chapter 8, there is 
considerable variation between clinicians in their preferred treatment, and they 
generally seem to prefer the treatment of their specialty. This has been shown in 
earlier research as well.40;41 It is important that clinicians are aware of their 
preferences and make these preferences transparent to their colleagues and 
patients. National treatment guidelines aid in identifying preference-sensitive 
decisions and creating choice awareness in clinicians. In general, treatment 
guidelines provide little or no recommendation on the patient’s role in deciding 
about treatment. The Dutch treatment guideline on colorectal cancer is the 
exception, as it explicitly states that the decision on preoperative radiotherapy is 
difficult and should involve the patient.6 Also, in the latest revision of these 
guidelines, several treatment recommendations have been rewritten to provide 
more room to choose between multiple treatment strategies. For all adjuvant 
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cancer treatments that may be preference-sensitive decisions, treatment 
recommendations should consider a similar approach. Preference-sensitive 
decisions could be identified and described as such in the guidelines, and the 





Step 1. Creating choice awareness. 
 Be aware that the recommendation from the multidisciplinary team is not a 
final decision. 
 When referring patients: State that the patient will be referred to another 
clinician to discuss the pros and cons of the possible treatment 
strategy/strategies. 
 At the start of the consultation: State that there are multiple treatment 
strategies available, that a decision needs to be made, and that the patient’s 
views matter. 




Step 2. Discussing treatment options in detail   
 
Communicating benefits and harms of treatment options 
Most cancer patients in developed countries prefer to have as much information 
as possible, regardless of whether it is positive or negative.45;46 Regarding 
treatment harms, over nine out of ten cancer patients indicate to have a strong 
need for this information.47 At the same time, the more information is given, the 
less patients usually remember.48 Depending on the total amount of information 
given, it is expected that about 40-80% of information is forgotten immediately 
after the consultation.49 Research suggests that this percentage decreases 
when information is tailored to the patient’s frame of reference.50;51 These 
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caveats do not imply that information should not be provided, but rather 
highlight the importance of consensus on which information should be given. 
In Chapter 3 we showed considerable variation both in the number and type 
of benefits and harms that were discussed during pre-treatment consultations 
between radiation oncologists and rectal cancer patients. This variation was 
seen between and within radiation oncologists. We found no consistent 
association between the oncologists’ information provision and patient 
characteristics. These findings imply that some patients receive limited 
information, while other patients are informed extensively on their treatment 
option(s). We expect that these findings are not specific to this clinical case and 
that such variation might be present in information provision in other 
preference-sensitive decisions as well.25 The variation in information provision 
indicates a lack of clarity on which benefits and harms should be discussed with 
patients, and this hampers the process of SDM.  
 
In our study described in Chapter 4, we reached consensus among treated 
rectal cancer patients and radiation oncologists on which benefits and harms of 
preoperative radiotherapy should be discussed in the pre-treatment 
consultation. We composed a core list of topics that should always be 
addressed. Interestingly, all topics on the core list are long-term benefits and 
harms of rectal cancer treatment. We assessed congruence between the results 
of our consensus-study and daily clinical practice and found that on average, 
patients receive information on fewer than half of the topics from the core list. 
Even more striking, local control (the benefit of preoperative radiotherapy) was 
the only topic from the core list that was addressed in almost one in ten 
patients. None of the harms was discussed. Previously, Pass and colleagues 
found that cancer patients actually notice that benefits of treatment are 
discussed more often than harms.52  
The need for implementing our core list in daily clinical practice has been 
clearly demonstrated. Incorporating the core list in the Dutch guidelines for the 
treatment of rectal cancer will be the first step.6 Using our core list as a checklist 
during the consultation can help clinicians to structure their conversation on the 
benefits and harms of treatment. Also, the core list could be offered to patients 
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prior to the consultation to encourage them to discuss certain topics with their 
radiation oncologist.  
 
In our Delphi-study, we found considerable overlap between topics that patients 
and oncologists consider necessary to be addressed during pre-treatment 
consultations. We also showed that patients are capable of prioritizing those 
benefits/harms that they think are most important. Patients’ perspectives are 
valuable when creating such core lists, and the method we used seems feasible 
for creating core lists for other treatments and other cancer types.53;54 A first 
step to ensure that patients are informed consistently and sufficiently 
throughout their treatment process is to develop a core list for the pre-surgery 
consultation between the surgeon and the rectal cancer patient. 
 
Time pressure as a barrier 
For oncologists, time pressure may be an important barrier to using our core list 
in daily clinical practice.23 In general, many fear that following the principles of 
SDM will lengthen the duration of consultation and present clinicians with 
greater time constraints than they already have. 23;28;55 In Chapter 3 we found 
that consultations last longer when more benefits and harms were addressed. 
However, in the current practice, a median of seven benefits and harms are 
discussed with patients eligible for short-course preoperative radiotherapy 
followed by a low anterior resection. For this patient group, our core list consists 
of only seven benefits/harms for female, and eight for male patients, which is 
similar to the current standard practice. 
 Although we found an increase of consultation length for the discussion 
on benefits and harms, we have no information on the association between 
consultation length and overall degree of SDM. Discussing benefits and harms 
of treatment is required by law and does not necessarily constitute SDM. 
However, there is no systematic increase in consultation duration when SDM is 
implemented.56 In the Netherlands, several health insurers have indicated that 
hospitals can claim costs for the extra time that clinicians may need to inform 
patients, even if these efforts do not lead to active treatment.57 Unfortunately, 
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no more than one in four hospitals offered this opportunity for extra time to their 
clinicians in the past year.58 Policy makers and health insurers should expand 
their collaboration and commitment to stimulating person-centred care that is 
unconstrained by time or reimbursement incentives for active treatment. 
 
Communicating probabilities 
Communicating probabilities relevant to the treatment decision is complex but 
essential, as probabilities often are the foundation of clinicians’ treatment 
recommendations and help determine the importance of potential benefits and 
harms. Research has shown that the format (i.e., words, numbers) in which 
probabilistic information is presented can have significant effects on patients’ 
interpretation of probability and on their readiness to undergo treatment.59-61 In 
a literature review on risk communication, Zipkin and colleagues recommended 
avoiding the use of only verbal labels (non-numerical probability statements) to 
improve patients’ understanding, since there is a high degree of variability in 
their interpretation.62-66 We confirmed these findings in our study described in 
Chapter 6, where we found considerable variation in how individuals interpret 
the verbal labels frequently-used in oncology. This variability could be especially 
problematic when clinicians communicate probabilities relevant to decision 
making. 
In Chapter 5, we found that radiation oncologists almost always mention 
probabilities of the beneficial effect of preoperative radiotherapy on local 
control. In contrast, probabilities of harms of treatment often go unmentioned. 
We found no consistent association between the oncologists’ provision of 
probabilities and patient characteristics, except that oncologists mentioned 
significantly fewer probabilities to less educated patients. If radiation oncologists 
communicated probabilities of local recurrence, they tended to present a 
relative risk, stating that preoperative radiotherapy will reduce the probability of 
local recurrence by half. In line with recommendations from Zipkin and 
colleagues, the radiation oncologists also presented the absolute risk or the 
absolute risk reduction in most cases.62 This approach helps to avoid steering 
patients towards one treatment strategy. In preoperative radiotherapy in rectal 
cancer, numerical probabilities are available and known to most Dutch 
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oncologists.6;67-69 We found that radiation oncologists only used verbal labels to 
convey a probability in one-third of the cases, despite the potential pitfall of 
variability in interpretation.  
We did not find an association between formats the oncologists used to 
convey probabilities and the correctness of patient’s estimates. In general, we 
found that patients tended to overestimate the probability of getting a local 
recurrence if adjuvant treatment with radiotherapy is foregone, and to 
underestimate the probability of harms occurring after radiotherapy treatment. 
This has been found in previous research as well.70 As it could have been 
difficult for patients to remember the exact probabilities mentioned, we also 
assessed whether patients estimated the correct effect of radiotherapy 
treatment on major treatment outcomes. Most patient estimated the effect of 
radiotherapy on local control correctly. In contrast, the effect on harms was most 
often estimated incorrectly. Over one-third of patients believed that adding 
radiotherapy to surgical treatment decreases the probability of faecal 
incontinence, while in fact, preoperative radiotherapy increases the risk from 
about 40 to 60% in patients without a stoma.71 This suggests that many patients 
are overly optimistic and believe that there is no harm in undergoing 
preoperative radiotherapy. An explanation for this belief might be sought in post 
hoc justification. In most cases, the treatment decision had already been made 
when we assessed patients’ understanding. As a result patients may have had 
the desire to justify the decision of undergoing preoperative radiotherapy as 
being the correct one, and one which will do them no harm.72 Individuals might 
have an optimistic bias, where they perceive that they are at less risk than their 
peers, enabling them to meet their psychological needs, such as hope and 
reassurance.70;73 
 
Evidence-based medicine and shared decision making 
In recent years, the relationship between SDM and evidence-based medicine 
has been increasingly recognized and explored.74 Evidence-based medicine has 
contributed to the understanding that many treatment strategies have marginal 
benefits, next to possible harms.18 In an SDM process, evidence can be brought 
into the consultation, and can be discussed with the patient, along with 
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discussions on the patient’s preferences.75 These patient’s preferences are, in 
addition to the medical evidence, a core ingredient of evidence-based medicine. 
If patients are not provided with the evidence, or if they do not understand the 
provided evidence, they are unable to form evidence-informed preferences, 
leading to preferences that might not be ‘true’.74;75 The steps of SDM are 
inextricably linked to evidence-based medicine.74 Oncologists should be careful 
to mention both benefit and harms of treatment with corresponding probabilities 
whenever possible and stay alert to patients’ potential misunderstanding.76  
In the example of preoperative radiotherapy in rectal cancer, evidence on 
benefit and harms of treatment – together with the numerical probabilities – is 
available and known to most Dutch oncologists. For many other treatments, this 
might not (yet) be the case. It could be that the occurrence of benefit or harms 
of treatment have not been established in randomized trials, that they have 
been established but not reported in literature, or that available evidence is 
conflicting. Randomized trials might have a focus on harms of treatment, but the 
specified outcomes might not necessarily be the same that patients believe are 
important. We must therefore ensure that all clinical trials assess and report 
possible harms of treatment that are of interest to the patient.  
It is also conceivable that clinicians, especially when they treat patients with 
different kinds of diseases, are unable to constantly be up to date with the latest 
evidence. In our studies on rectal (Chapter 3) and endometrial (Chapter 8) 
cancer, clinicians indicated that they treat about two or three patients per 
month, on average, with these conditions. In both studies, there were clinicians 
that reported treating fewer patients per month. Thus, all clinicians’ knowledge 
of the evidence and recommendations from the guidelines may not be 
completely up to date, which is undesirable for relatively common diseases like 
rectal cancer. Regarding the provision of information, one way of enabling 
clinicians to communicate the latest evidence to their patients is to provide 
them with easy-to-use tools.53 Examples of such easy-to-use within-consultation 
tools are Option Grids, developed by Elwyn and colleagues.77 These grids are 
summary tables of answers to questions that patients frequently ask, 
accompanied by a document containing the latest evidence.78 Also, prediction 
models, such as Adjuvant online for early-stage breast cancer, might help 
clinicians in using the latest available evidence, and in determining and 
communicating personalized probabilities.79 More general, we must ensure that 
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all patients are treated by a clinician who is up to date and experienced in 
treating patient with their disease.53 Centralizing care may be one way to 
accomplish this.53 Centralizing care could be done on an institutional level, or on 
a clinician level (specialization), meaning that clinicians are required to treat a 
minimum number of patients per year. To come to this minimum number, 
clinicians could cover multiple (regional) institutes. Specialized nurse 
practitioners could also play a role in supporting oncologists in informing 
patients; however, we must ensure that providing information on benefits and 
harms of treatment takes place before the treatment decision is made. The 
latter might sound evident, but a recent study showed that harms of treatment 




Step 2. Discussing treatment options in detail. 
 Discuss both benefits and harms of treatment with the patient. 
 Create and use a core list of benefits and harms to assist the discussion on 
adjuvant treatment. 
 Avoid the use of verbal labels (non-numerical statements) when possible.62  
 When presenting a relative risk (“half the risk”), present absolute risks as 
well (“from 11 to 6%”).62 





Step 3. Discussing patients’ values and preferences and deciding what is best 
 
As Street and de Haes stated, “clinicians are experts in medical options and 
their clinical implication, but patients are experts in terms of the impact of these 
decisions on their everyday living”.81 In the previous paragraphs, we have seen 
how oncologists provide patients with relevant information on the treatment(s). 
This is minimal and necessary – but not sufficient – condition for SDM. It is 
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crucial that patients convey their values regarding benefits and harms of 
treatment and their treatment preferences to their treating oncologist. 
 
Discussing and considering patients’ values and treatment preferences 
Involving patients in the decision making process is justified by the extent to 
which patients’ values and preferences regarding treatments and treatment 
outcomes differ.82 As research has shown great variation in patients’ values and 
preferences,83;84 and how difficult it is to predict these84-86 it is important for 
clinicians to explore the patient’s values and treatment preferences so that 
these can be considered in choosing a treatment strategy that best fits the 
patient.87 The SDM model states that patients’ values and treatment 
preferences should be elicited,2;27;88 but the evidence available suggests that 
this does not happen in daily clinical practice.89-91 
In Chapter 7 we showed that rectal cancer patients’ values concerning 
benefits and harms of preoperative radiotherapy are discussed for only one out 
of ten benefits/harms addressed. Overall, more than half of patients did not 
voice any values during their consultation with the radiation oncologist. If values 
regarding benefits or harms of treatment were discussed, they most often 
concerned long-term major outcomes of radiotherapy, such as local recurrence, 
faecal incontinence and different aspects of sexual dysfunction. This is 
consistent with our findings in Chapter 4, where we showed that patients and 
oncologists consider these long-term major outcomes necessary to discuss in 
the pre-treatment consultation. Patients’ treatment preferences were voiced in 
only about one in five consultations. 
Evidence shows that it is difficult for clinicians to predict patients’ values or 
treatment preferences, and we must therefore be alert to the ‘silent 
misdiagnosis’ of these values and preferences.92 After providing patients with all 
relevant information, oncologists can explicitly invite patients to share their 
views.30 In our study described in Chapter 7, we showed that this happens in 
about one in five consultations. In these consultations, the radiation oncologist 
explicitly indicated that the patient’s views were to be considered in deciding 
about preoperative radiotherapy. In several consultations, the patient did not 
voice any values or treatment preferences in response to the oncologist’s 
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invitation, and the oncologist did not probe any further. Patients’ non-response 
might be due to the unexpected invitation from oncologists to voice their values 
and treatment preferences. As discussed above (Chapter 2), oncologists rarely 
indicate upfront that a treatment decision needs to be made. Therefore, many 
patients might not realize that foregoing (neo-)adjuvant treatment is a viable 
option and that they may use the provided information to think about their 
values and treatment preferences and discuss these with their oncologist.93 
Appropriately creating choice awareness might be a first step for patients to 
realize that their values and treatment preferences are of importance in the 
treatment decision, and that they should therefore voice these views and 
participate in treatment decision making. 
 
Despite the above, most patients with rectal cancer felt they had shared the 
treatment decision with their radiation oncologist to some extent (Chapter 7). 
We found that patients perceived a more active role in treatment decision 
making when their values or treatment preferences had been discussed during 
the consultation, or when the oncologist indicated to consider these values or 
preferences in the decision making process. This is an important finding, which 
is consistent with the SDM model. We thus showed that discussing and explicitly 
considering patients’ values or preferences will not only help choosing what is 
best for each individual patient, it will also make patients feel more involved in 
deciding about treatment. Perceived active involvement has been shown to lead 
to better patient outcomes.9;94 
 
Preference for active treatment 
On average, rectal cancer patients require only a small beneficial effect of 
preoperative radiotherapy to consider it worthwhile,83 which we also found true 
for patients with endometrial cancer regarding postoperative vaginal 
brachytherapy. However, large variation existed between patients in individual 
treatment preferences (Chapter 8).83 Previous research has shown that cancer 
patients have a strong preference for seeking active treatment.37 Cancer 
patients also describe considerable pressure from family members, clinicians or 
support groups to seek active treatment.37 In our study described in Chapter 8, 
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more than half of the irradiated and non-irradiated patients with endometrial 
cancer indicated choosing postoperative vaginal brachytherapy, even if it would 
have no additional benefit. This seems irrational, but has been found in earlier 
studies as well.72;83 The strong preference for active treatment is possibly 
caused by anticipated regret and the wish to have done everything one could. 
We must be aware that the ‘best’ treatment option, for some patients, may not 
only depend on the medical outcomes that patients can expect to experience, 
but also on whether these outcomes are achieved actively or passively.95 As 
stated above, the principles of SDM are especially relevant when there is more 
than one medically reasonable option available and the treatment decision is 
preference-sensitive. SDM does not imply that all possible treatment strategies, 
including medically unreasonable options, are offered to patients. 
 
Involvement in the decision making process versus involvement in the final 
decision 
One of the most often used arguments against implementing SDM is that 
patients do not want to participate in decision making.23;96 In Chapter 8 we 
showed that most patients with endometrial cancer preferred to share the 
decision with their clinician. This has also been found in previous research, in 
cancer care and other settings.97-99 Some argue that clarifying the patient’s 
desired role should be a separate step or sub-step in the SDM model.96;100 If so, 
research implies that this step should occur after providing the patient with 
information. Many patients who are initially hesitant to be actively involved in 
decision making, prefer a more active role once they have received information 
on possible treatment options.101 It is important to realize that SDM is 
comprised of an entire process of steps to be taken, instead of just a final 
decision only.96 Even if the patient does not wish to make the final decision, the 
clinician should create choice awareness, discuss the treatment options in detail 
and elicit the patient’s values and preferences in order to incorporate the 
patient’s view in a treatment recommendation. By that, a treatment 
recommendation does not hamper the process of SDM, as long as this 




Values clarification methods 
Our study described in Chapter 7 showed that patients’ values and treatment 
preferences are not systematically elicited during the pre-treatment 
consultations. We have seen that the patient might need more encouragement 
from the oncologist, or, as some patients in our study indicated, more time to 
think about their preferences. One way of helping patients to gain insight on 
their values and preferences is to offer them methods to help them become 
clear on their values.102 This values clarification method can be completed prior 
to the consultation, or perhaps even better: following the consultation but prior 
to the treatment decision. We are working on the implementation of such a tool 
regarding preoperative radiotherapy in rectal cancer.103-105 The effect of this tool 
on the communication about patients’ values and preferences during the 
consultation, and on patients’ participation in the decision making process, as 
well as the patients’ satisfaction with the tool will be evaluated.  
 
Decision support tools 
In the course of this chapter, several tools to support the conversation between 
clinicians and patients and the process of treatment decision making, such as 
Option Grids, prediction models and values clarification methods, have been 
mentioned. These tools are so-called ‘decision support tools’. Decision support 
tools are developed to encourage an SDM process, but it is important to be very 
clear that using decision tools is not equivalent to SDM.106 Nationally as well as 
internationally, significant investments have been made in the development and 
implementation of these interventions.107;108 The value of decision support tools 
focusing on the second and third step of SDM has been clearly demonstrated,107 
but despite great efforts, they have not yet become part of routine clinical 
practice.109;110 Several barriers for implementation are mentioned in the 
literature, such as lack of clinical support, competing priorities and scheduling 
problems.109 One could doubt whether the development and maintenance of 
such disease-specific tools is, at this point in time, the first priority. As stated 
earlier, concentrating on the first step of SDM and creating choice awareness in 
all patients – or in all citizens – might be a universal, simple, inexpensive, yet 
effective way in empowering patients to participate in medical decision making. 
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Once there is a change of mind set and people are aware that there are choices 
to be made in healthcare and that their personal views matter, the effect of 
disease-specific decision support tools might be enlarged. Choice awareness 




Step 3. Discussing patients’ values and preferences and deciding what is best. 
 Indicate that the patient’s views are important to consider in treatment 
decision making. 
 Explicitly invite patients to share their values regarding benefits and harms of 
treatment and their treatment preferences.  
 SDM is not about the decision, it is about the conversation.111 Even if the 
patient refers the final decision to you, make a treatment recommendation 






In this thesis, we aimed to gain insight in the process of shared decision making 
in the setting of adjuvant cancer treatments. We observed clinician-patient 
consultations in daily clinical practice, and developed a core list of information 
that should be provided in the pre-treatment consultation. We showed that the 
key steps of shared decision making are followed to a limited extent. Choice 
awareness is rarely created in pre-treatment consultations on (neo-)adjuvant 
cancer treatment, and the option of foregoing these treatments is omitted 
consistently (Step 1). There is large variation in information provision on possible 
treatment strategies. Patients tend to overestimate the beneficial effect of 
treatment, and to underestimate the probability of harms (Step 2). Finally, 
patients’ values and treatment preferences are elicited in only a minority of 
consultations. If patients voice their values or treatment preferences, or if the 
oncologist indicates to consider these, patients perceive a significant more 
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active role in the decision making process (Step 3). Our results show that 
opportunities are missed to engage patients in a process of shared decision 
making, but small changes in doctor-patient communication can facilitate 
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In healthcare settings, shared decision making is increasingly the preferred 
approach to making decisions when more than one reasonable option is 
available (‘preference-sensitive’ decisions). To accomplish shared decision 
making, three key steps are followed: 1) Creating choice awareness, 2) 
Discussing treatment options in detail, and 3) Discussing patients’ values and 
preferences and deciding what is best. Taking these three steps as the starting 
point, the overall aim of this thesis was to assess to what extent the key steps of 
shared decision making are followed in preference-sensitive decisions regarding 
(neo-)adjuvant cancer treatment in daily clinical practice. 
 
Part I. Creating choice awareness 
The first step in shared decision making is for both the clinician and the patient 
to define and/or explain the problem and to acknowledge that a decision needs 
to be made. Both parties should be aware that more than one reasonable option 
is available and that there is no ‘best choice’. If doing nothing (for example, 
foregoing adjuvant treatment) is a viable option, it should be presented as such. 
In Chapter 2, we assess whether in pre-treatment consultations on (neo-) 
adjuvant cancer treatment, oncologists explicitly state that a treatment decision 
needs to be made as a ‘reason for the encounter’. Our results show that 
oncologists rarely express this need. Instead, they use the consultation to 
explain the one treatment strategy that they recommend. The option of forgoing 
(neo-)adjuvant treatment is consistently omitted during the pre-treatment 
consultation, which might lead to the patient not realizing that this is a viable 
option. Failing to perform the first key step of a shared decision making process, 






Part II. Discussing treatment options in detail 
The second step in shared decision making is to discuss the possible treatment 
options in more detail. All relevant benefits and harms of the presented options 
should be addressed, as well as their respective probabilities, which can help 
weighing the benefits and harms.  
In Chapter 3, we describe what information radiation oncologists provide 
about possible benefits and harms of preoperative radiotherapy during the pre-
treatment consultation with rectal cancer patients. We found considerable 
variation between and within radiation oncologists in information provision, 
which could not be explained by patient characteristics. Oncologists addressed 
between 2 and 13 benefits/harms per consultation, adding up to a total of 30 
different treatment outcomes mentioned in 81 consultations.  
Given the large variation in information provision, we then reached 
consensus among radiation oncologists and rectal cancer patients on which 
benefits and harms should be addressed during the pre-treatment consultation 
in Chapter 4. We conducted a four-round Delphi study in which we asked 
radiation oncologists and rectal cancer patients to indicate the importance of 
addressing each benefit/harm. Oncologists and patients reached consensus 
that six topics should be addressed with all patients: local control, survival, long-
term altered defecation pattern, faecal incontinence, perineal wound healing 
problems, and advice to avoid pregnancy. Additionally, three items should be 
discussed with male patients: erectile dysfunction, ejaculation disorder, and 
infertility, and four with female patients: vaginal dryness, pain during 
intercourse, menopause, and infertility. Of note, all items in the final core list are 
long-term benefits and harms. Finally, in this chapter, we assess the congruence 
between the core list from the Delphi-study and daily clinical practice. On 
average, less than half of the topics from the core list were addressed during the 
consultation. Almost one in ten patients received no information on any adverse 
effects that should have been addressed, according to both radiation 





Chapter 5 describes whether and how radiation oncologists provide probabilistic 
information during the pre-treatment consultations with rectal cancer patients, 
and how patients estimate probabilities of major treatment outcomes after this 
consultation. Results showed that in almost two-third of the times that a benefit 
or harm was discussed, the oncologist also mentioned the probability of its 
occurrence, albeit significantly less frequently to patients with lower education. 
Oncologists virtually always mention probabilities of the beneficial effect of 
preoperative radiotherapy on local control but probabilities of harms often go 
unmentioned. After the consultation, patients tended to overestimate the 
probability of getting a local recurrence if preoperative radiotherapy is foregone 
(e.g., treatment with surgery alone), and to underestimate the probability of 
harms occurring after radiotherapy treatment. The effect of preoperative 
radiotherapy on local recurrence was most often interpreted correctly. In 
contrast, the effect of preoperative radiotherapy on faecal incontinence and 
sexual dysfunction was often estimated incorrectly. Over one-third of patients 
believed that adding radiotherapy to the main surgical treatment decreases the 
probability of faecal incontinence.  
The verbal labels (non-numeric probability statements) used to convey 
probabilities during these pre-treatment consultations were offered to a sample 
of adult Dutch population, as proxies for newly-diagnosed cancer patients, in 
Chapter 6. We found considerable variation in how individuals interpreted the 
verbal labels, with significantly lower estimates in the context of cancer 
recurrence compared to nausea. Participants with low numeracy tended to 
differentiate less between the labels. The same tendency was found for 
educational level and health literacy, but not statistically significant. 
 
Part III. Discussing patients’ values and preferences and deciding what is best 
In the third step, patients’ ideas, concerns, and expectations should be 
discussed and considered. Both parties should decide what is best and agree on 
the follow-up, which could also imply postponing the final decision. 
Chapter 7 focuses on the extent to which rectal cancer patients’ values 
concerning benefits and harms of treatment, and patients’ treatment 
preferences are voiced and explicitly considered when deciding about 
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preoperative radiotherapy. Results showed that less than half of patients voice 
one or more values during the consultation. In total, patients only expressed 
their values regarding one of ten benefits and harms addressed. Patients’ 
treatment preferences were discussed in one in five consultations. If patients’ 
values or treatment preferences had been addressed or if the oncologist 
indicated that these were of importance when deciding about treatment, the 
patient perceived that he or she had a significantly more active role in the 
decision making process. 
In Chapter 8, we explore treatment preferences of patients with endometrial 
cancer and treating clinicians regarding postoperative vaginal brachytherapy and 
a postoperative watchful waiting policy. We also evaluate their preferred and 
perceived involvement in treatment decision making. Our results showed that 
patients prefer brachytherapy over a watchful waiting policy for a lower 
treatment benefit in local control than clinicians. Irradiated patients and 
radiation oncologists required a significantly lower minimally desired benefit 
than non-irradiated patients and gynaecologists, respectively. However, there 
was substantial variation within the groups of patients and clinicians. Most 
participants preferred the patient and clinician to share in the decision about 
brachytherapy, but irradiated patients – who had actually faced the decision 




We aimed to gain insight in the process of shared decision making in (neo-) 
adjuvant cancer treatments. To this end, we observed clinician-patient 
consultations in daily clinical practice, and developed a core list of information 
that should be provided in the pre-treatment consultation. We showed that the 
key steps of shared decision making are only followed to a limited extent. Our 
results show that opportunities are missed to engage patients in a process of 
shared decision making. Subsequently, recommendations for future research 




Samenvatting (Dutch Summary) 
 
Gedeelde besluitvorming of ‘shared decision making’ is de afgelopen decennia 
steeds belangrijker geworden in de gezondheidszorg, zeker als het gaat om 
voorkeursgevoelige beslissingen. Om te spreken van een succesvol proces van 
gedeelde besluitvorming, zijn er drie belangrijke stappen die gevolgd dienen te 
worden: 1) Creëren van keuzebewustzijn, 2) In detail bespreken van 
behandelingsopties, en 3) Bespreken van de waarden en voorkeuren van 
patiënten en besluiten wat te doen. Met deze drie stappen als uitgangspunt, 
was het doel van dit proefschrift om kennis te vergaren over de mate waarin de 
stappen van gedeelde besluitvorming worden genomen bij voorkeursgevoelige 
beslissingen rondom (neo-)adjuvante oncologische behandelingen in de 
dagelijkse klinische praktijk. 
 
Deel I. Creëren van keuzebewustzijn 
De eerste stap in gedeelde besluitvorming is dat zowel de arts als de patiënt de 
zorgvraag definiëren en/of uitleggen en erkennen dat er een beslissing gemaakt 
moet worden. Beide partijen moeten zich ervan bewust zijn dat er meerdere 
opties zijn en dat er geen overduidelijke ‘beste optie’ is. Als een afwachtend 
beleid (of, bij voorbeeld, afzien van adjuvante behandeling) een reële optie is, 
dan dient deze als zodanig te worden gepresenteerd. 
In Hoofdstuk 2 hebben we onderzocht of oncologen expliciet aangeven dat 
het pre-behandelingsconsult rondom (neo-)adjuvante behandeling bedoeld is 
om een behandelingskeuze te maken. Uit de resultaten bleek dat oncologen 
zelden met de patiënt bespreken dat er een behandelingskeuze gemaakt moet 
worden. In de meeste consulten gaven oncologen aan dat de patiënt op consult 
was om uitleg over de adjuvante behandeling te krijgen. De optie om af te zien 
van adjuvante behandeling werd in geen enkel consult besproken, waardoor 
patiënten zich wellicht niet realiseren dat dit een mogelijke optie is. Doordat 
oncologen de eerste stap in het proces van gedeelde besluitvorming overslaan, 
missen zij een cruciale kans om patiënten te betrekken en om het proces van 
gedeelde besluitvorming te faciliteren. 
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Deel II. In detail bespreken van behandelingsopties 
De tweede stap in gedeelde besluitvorming is dat de mogelijke 
behandelingsopties in detail worden besproken. De relevante voor- en nadelen 
van alle opties dienen te worden besproken, evenals de kansen op deze voor- en 
nadelen. Het bespreken van de kansen kan lastig zijn, maar deze kansen zijn 
belangrijk om de voor- en nadelen af te wegen. 
In Hoofdstuk 3 beschrijven we de informatievoorziening over mogelijke voor- 
en nadelen van preoperatieve radiotherapie bij rectumcarcinoom. We 
onderzochten welke voor- en nadelen worden besproken in het pre-
behandelingsconsult tussen de radiotherapeut en de patiënt met een 
rectumcarcinoom. Er was aanzienlijke variatie, in hoeveel en welke voor- en 
nadelen van preoperatieve radiotherapie besproken werden voorafgaand aan de 
behandeling. Deze variatie werd gevonden zowel tussen radiotherapeuten als 
per radiotherapeut en kon niet verklaard worden op basis van karakteristieken 
van de patiënt. Oncologen adresseerden tussen de 2 en 13 voor-/nadelen per 
consult. In de 81 geanalyseerde consulten tezamen werden 30 verschillende 
voor- en nadelen besproken. 
Vanwege de gevonden variatie in informatievoorziening, wilden wij in 
Hoofdstuk 4 consensus bereiken tussen radiotherapeuten en patiënten met een 
rectumcarcinoom over welke voor- en nadelen in het pre-behandelingsconsult 
besproken zouden moeten worden. In een Delphi consensusstudie, bestaande 
uit vier ronden, vroegen we radiotherapeuten en patiënten om per voor-/nadeel 
aan te geven of deze besproken dient te worden. De radiotherapeuten en 
patiënten bereikten overeenstemming dat zes onderwerpen met alle patiënten 
besproken moeten worden, namelijk: lokale controle, overleving, veranderd 
ontlastingspatroon op lange termijn, fecale incontinentie, perineale 
wondgenezingsproblemen en het advies om zwangerschap te voorkómen. 
Daarnaast bereikten zij consensus dat drie onderwerpen met mannelijke 
patiënten besproken moeten worden, namelijk erectiestoornissen, 
zaadlozingsproblemen, en onvruchtbaarheid; en vier met vrouwelijke patiënten, 
namelijk vaginale droogheid, pijn bij gemeenschap, menopauze en 
onvruchtbaarheid. In dit hoofdstuk onderzochten we eveneens de congruentie 
tussen de kernlijst van voor- en nadelen die door de radiotherapeuten en 
patiënten was samengesteld met de dagelijkse klinische praktijk. We vonden 
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dat gemiddeld minder dan de helft van de onderwerpen op de kernlijst in het 
consult werden besproken. Eén op de tien patiënten werd over geen enkel 
nadeel van de kernlijst geïnformeerd.  
 
Hoofdstuk 5 beschrijft óf en op welke manier radiotherapeuten kansen 
communiceren tijdens het pre-behandelingsconsult met patiënten met een 
rectumcarcinoom. Ook beschrijft het hoofdstuk hoe de patiënten de kansen van 
de belangrijkste behandelingsuitkomsten na afloop van het consult inschatten. 
In twee-derde van de gevallen dat een voor- of nadeel werd besproken, 
noemden de radiotherapeuten ook bijbehorende kansen. Dit gebeurde echter 
significant minder vaak bij patiënten met een lagere opleiding. 
Radiotherapeuten gaven in bijna alle gevallen dat lokale controle besproken 
werd ook kansinformatie, maar lieten kansen over nadelen van radiotherapie 
vaker achterwege. Patiënten hadden de neiging om de kans op een lokaal 
recidief, indien wordt afgezien van preoperatieve bestraling, te overschatten. 
Daarnaast onderschatten zij de kans op nadelen van preoperatieve 
radiotherapie. Hoewel het effect van radiotherapie op locale controle door de 
meeste patiënten goed werd ingeschat, werd het effect op fecale incontinentie 
en seksuele problemen vaak verkeerd geïnterpreteerd. Ruim een derde van de 
patiënten dacht dat preoperatieve radiotherapie de kans op fecale incontinentie 
verkleint. 
De kanswoorden (zoals ‘soms’, ‘vaak’) die tijdens de pre-
behandelingsconsulten werden gebruikt om een kans uit te drukken, zijn 
aangeboden aan een steekproef van de volwassen Nederlandse bevolking, als 
proxies voor nieuw gediagnosticeerde oncologische patiënten, in Hoofdstuk 6. 
We onderzochten hoe individuen deze frequent gebruikte kanswoorden 
interpreteren in de context van twee uitkomsten van oncologische 
behandelingen. De resultaten lieten een aanzienlijke variatie zien in hoe deze 
kanswoorden worden geïnterpreteerd. De kansen werden significant lager 
ingeschat bij kanswoorden in de context van een lokaal recidief, vergeleken met 
de context van misselijkheid. Deelnemers met een lage cijfervaardigheid 
(“numeracy”) maakten minder onderscheid in de interpretatie van de 
verschillende kanswoorden. Dezelfde tendens werd gevonden voor 
opleidingsniveau en gezondheidsvaardigheden (“health literacy”).  
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Deel III. Bespreken van de waarden en voorkeuren van patiënten en besluiten 
wat te doen. 
In de derde stap van gedeelde besluitvorming dienen de waarden, 
verwachtingen en zorgen van patiënten te worden besproken en te worden 
meegenomen in het bepalen van een behandeling. Beide partijen moeten het 
eens zijn met de beslissing en met de vervolgstappen. Dit kan ook inhouden dat 
de beslissing wordt uitgesteld. 
Hoofdstuk 7 beschrijft in hoeverre de waarden van patiënten ten opzichte 
van voor- en nadelen van preoperatieve radiotherapie bij rectumcarcinoom, en 
hun behandelingsvoorkeuren worden besproken en expliciet worden 
meegenomen in de behandelingsbeslissing. Onze resultaten lieten zien dat 
minder dan de helft van de patiënten met een rectumcarcinoom één of 
meerdere waarden uitten tijdens het pre-behandelingsconsult. In totaal uitten 
patiënten hun waarden voor ongeveer één op de tien voor-/nadelen besproken. 
In één op de vijf consulten gaven patiënten aan welke behandeling hun voorkeur 
had. Als patiënten hun waarden of hun behandelingsvoorkeuren uitten, of als de 
radiotherapeut aangaf dat deze belangrijk zijn in het maken van een beslissing, 
ervoeren patiënten een significant grotere betrokkenheid in de besluitvorming. 
In Hoofdstuk 8 onderzochten we de behandelingsvoorkeuren van patiënten 
met een endometriumcarcinoom en behandelend artsen ten opzichte van 
postoperatieve vaginale brachytherapie en een postoperatief afwachtend beleid. 
Daarnaast brachten we in kaart in hoeverre zij betrokken wilden worden in de 
besluitvorming en wat de ervaren betrokkenheid van reeds bestraalde patiënten 
was. Vergeleken met de artsen gaven de patiënten voor een lagere baat in 
lokale controle de voorkeur aan postoperatieve brachytherapie. Bestraalde 
patiënten en radiotherapeuten hadden daarnaast een significant lagere baat 
van brachytherapie nodig om voor deze behandeling te kiezen dan niet-
bestraalde patiënten en gynaecologen. Er was echter grote variatie binnen en 
tussen de groepen van patiënten en artsen in de gewenste baat. Hoewel de 
meeste artsen en patiënten samen de behandelingsbeslissing zouden willen 
maken, gaven bestraalde patiënten (die daadwerkelijk voor de keuze hadden 





Het doel van dit proefschrift was om inzicht te krijgen in het proces van gedeelde 
besluitvorming rondom adjuvante oncologische behandelingen. Hiertoe hebben 
we consulten tussen artsen en patiënten geobserveerd in de dagelijkse klinische 
praktijk, en een kernlijst ontwikkeld van onderwerpen die tijdens het consult 
besproken dienen te worden. We lieten zien dat de drie stappen van gedeelde 
besluitvorming slechts beperkt worden genomen. Onze resultaten maken 
duidelijk dat er kansen worden gemist om patiënten te betrekken in een proces 
van gedeelde besluitvorming. In het proefschrift geven we aanbevelingen voor 
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